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ABSTRACT 
In South Africa, the anti-HIV-1 activity of various indigenous plants has not been 
studied extensively. Most of the phytochemical screening work has focused on 
anti-cancer activity with less attention given to infectious diseases. A large 
proportion of South Africans (70-80%) still rely on traditional medicines for 
treatment of various ailments. And, therefore, there is a need to evaluate and 
validate the effectiveness of the traditional medicines. The aim of this study was 
to identify, screen, phytochemically characterize and isolate bioactive compounds 
from a South African herbal extract that exhibit the best anti-HIV-1 activity. 
Three extracts were prepared: an ethanol extract, a dereplicated ethanol extract 
and an aqueous extract from a herbal concoction comprised of a mixture of six 
plants. These herbal concoctions were investigated for anti-HIV-1 subtype C 
activity.   
Phytochemical profiling of the ethanol- and dereplicated ethanol- extracts from 
the herbal concoctions showed the presence of intermediate polar compounds 
(flavonoids, alkaloids, sugars and terpenes) for both extracts, while the aqueous 
extract contained predominantly highly polar compounds.  
Anti-HIV-1 screening of the three extracts showed that the ethanol and 
dereplicated ethanol herbal- extracts had the best anti-reverse transcriptase 
activity. The ethanol extract had mean IC50 values of 56.53, 53.96 and 55.39 
µg/ml against MJ4, Du179 and CM9 HIV-1 subtypes C isolates, respectively. The 
dereplicated ethanol extract had mean IC50 values of 51.87, 47.56 and 52.81 
µg/ml against MJ4, Du179 and CM9 HIV-1 isolates, respectively. The aqueous 
extract was inactive against HIV-1 activity. 
Moreover, both the ethanol- and dereplicated ethanol- extracts showed activity 
against HIV neutralization. The ethanol- and dereplicated ethanol- extracts had 
mean IC50 values of 36.33 and 32.06 µg/ml, respectively. Furthermore, they also 
potently neutralized Vesicular stomatitis virus (VSV) yielding mean IC50 values 
of 24.91 and 20.82 µg/ml for ethanol- and dereplicated ethanol- extracts, 
respectively. All extracts were inactive against Murine leukemia virus (MLV).  
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The isolation and phytochemical characterization of the bioactive compound(s) 
was done by utilizing various chromatographic and spectroscopic methods. Four 
homoisoflavanoids were isolated and tested for anti-HIV-1 subtype C activity. 
Three compounds (1, 3a and 3b) were inactive while compound 2 was found to be 
bioactive against HIV-1 reverse transcriptase (RT) and yielded mean IC50 values 
of 7.23 ± 1.88, 12.83 ± 0.41 & 12.81 ± 0.10 µg/ml for MJ4, CM9 and Du179 
HIV-1 subtype C isolates, respectively. Compound 2 had a mean CC50 value of 
23.08 ± 0.1981 µg/ml against HEK293T cells.    
Overall, the data suggested that ethanol- and dereplicated ethanol- herbal extracts 
possess direct and indirect anti-HIV-1 activity. They possess a cocktail of 
phytochemicals that can inhibit HIV-1 RT, HIV-1 entry. Furthermore, these 
extracts possess phytochemicals that can lower the activation of inflammatory 
responses during an infection and, hence, reduction in the number new cells 
infected during the course of HIV-1 infection. Moreover, they possess 
phytochemicals that have antioxidant activity which, in relation to HIV infection, 
results in a boosted immune system response in order to ward off the virus. 
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1 CHAPTER 1 
      Literature review 
1.1 HIV/AIDS background 
Thirty years after the identification of Human Immunodeficiency Virus (HIV), a cure for the 
HIV infection still has to be found. HIV is believed to have been a result of the genetic 
mutation of the virus that has been endemic in the wild life of some areas in Central Africa 
(Tortora, Funke and Case, 2010). Genetic analysis of the HI virus led to the conclusion that 
the virus evolved from the monkey infecting virus known as: Simian immunodeficiency virus 
(Maartens et al., 2014). Human immunodeficiency virus/ acquired immunodeficiency 
syndrome (HIV/AIDS), is a type of zoonotic disease which is caused by two viral strains, 
namely, HIV-1 and HIV-2. HIV-1 is the primary virus strain infecting the human race 
worldwide and is related to SIV infecting chimpanzees in Central Africa (Maartens, et al., 
2014; Tortora et al., 2010). HIV-2, on the other hand, is a less virulent strain mainly found in 
the West African region. HIV-2 has arisen from the SIV infecting sooty mangabey monkeys 
in West Africa (Maartens, et al., 2014; Tortora et al., 2010). HIV-2 is limited to West Africa 
and causes a similar illness as HIV-1, but progression to immunodeficiency is slower and is 
less infectious than HIV-1 (Sharp and Hahn, 2011) 
The HIV epidemic emerged following infections with simian immunodeficiency viruses that 
naturally infect African primates; it is believed that bush meat hunters were probably the first 
group to be infected with HIV (Sharp and Hahn, 2011). Cross-species transmission from 
other primates into humans probably occurred by blood contamination through hunting and 
handling of „bushmeat‟ (Lever, 2009).  
The HIV infects vital immune system cells such as CD4+ T cells, monocytes, macrophages, 
and dendritic cells (Tortora et al., 2010; Cos et al., 2004). These cells harbour infectious HIV 
for years. After infection, the person is in an asymptomatic period which may last for several 
months to years, prior to the development of Acquired Immunodeficiency Syndrome (AIDS). 
HIV causes profound immunosuppression (Cos et al., 2002) leading to these observed clinical 
symptoms: weight loss, persistent fever, night sweats, diarrhoea, headache and opportunistic 
infections such as thrush, lymphadenitis, skin rashes, shingles, chicken pox, Kaposi sarcoma, 
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pneumonia, oesophageal candidiasis, mycobacterial infection, cryptococcosis and toxoplasma 
encephalitis (Vermani and Garg, 2002). It is important to note that not everyone experiences 
all these symptoms when they are diagnosed with AIDS.  
Acquired immunodeficiency syndrome (AIDS) is defined as a multifactorial disease 
portrayed by gradual obliteration of a person's immune system whereby the white blood cells 
(especially T-lymphocytes) become deficient (Cos et al., 2004) leading to observable clinical 
symptoms that are associated with immune deficiency and autoimmune inflammation 
(Barbaro and Klatt, 2002; Cos et al., 2002; Vermani and Garg, 2002). The decline in CD4+ 
T-cell count due to HIV infection occurs by means of a series of processes, including 
apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of 
infected CD4+ T cells by CD8+ cytotoxic white blood cells (Dambuza et al., 2005; Cos et al., 
2002; Tortora et al., 2010). Research indicates that lower levels of CD4+ cells render patients 
susceptible to opportunistic diseases which lead to the development of AIDS. 
Memory mature T-helper cells expressing the surface CD4 protein receptor (CD4+ T-cells) 
that are infected by HIV are regarded as the most important cellular reservoirs for this virus. 
The existence of this memory cell reservoir is due to the biological ability of these cells to 
survive for long periods of time, ranging from months to years, thereby equipping the host 
with the ability to respond rapidly to previously encountered infections (Deeks, 2003; 
Saksena and Potter, 2003). Together with viral load, CD4+ T-cell count is important in 
tracking the progress of HIV infection towards the AIDS state. The CD4 count is also used to 
select patients for antiretroviral therapy (ART) and assessment of the therapeutic effect 
following treatment (Dambuza et al., 2005). According to the Centre for Disease Control 
(CDC) and World Health Organization (WHO), a patient is diagnosed with AIDS if the 
CD4+ T cells count is equal to or less than 200/mm
3
 as shown in Figure 1.1.  
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Figure 1.1: Viral load and CD4 count with the progression of HIV-1 infection. Red line 
represents CD4+ T cell population and grey represents HIV population in blood. (Taken from 
Tortora et al., 2010)  
1.2 HIV/AIDS epidemiology and statistics  
HIV-1 is classified into distinctive groups named M (main), N (non-M or O) and O (outlier) 
(Sharp and Hahn, 2011; Tortora et al., 2010). These groups represent three separate 
transmission events from chimpanzees (Sharp and Hahn, 2011). Recent studies have found 
another group called P which is closely related to the simian immunodeficiency virus 
infecting gorillas (SIVgor) and it is believed that it most likely arose from an independent 
gorilla to human transmission (Sauter et al., 2011; Sharp and Hahn, 2011). 
Analogous to HIV-2, the HIV-1 groups: N, O, and P are limited to West African countries. 
The HIV group M, which is the causative agent of the global HIV/AIDS pandemic, emerged 
about a century ago and is made up of nine clades: A–D, F–H, J, and K. HIV-1 subtype C is 
predominantly found in Africa and India, and was responsible for 48% of cases of HIV-1 
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infections in 2007 worldwide (Hemelaar et al., 2011). Subtype B is predominantly found in 
the Americas, Western Europe and Australia. Currently, recombinant subtype strains of HIV 
are becoming more common (Hemelaar et al., 2011). 
The apparent genetic diversity of HIV-1 is due to the lack of proofreading ability of reverse 
transcriptase which makes it error prone resulting in higher rates of mutation. 
The epidemiology of HIV/AIDS especially in developing countries is further influenced 
(among other factors) by men who sleep with men (Birrell et al., 2013), sharing of needles in 
the case of intravenous drug users and addicts (Degenhardt et al., 2010). The epidemic in 
southern Africa is spreading mainly through heterosexual exposure, high rates of labour 
migration, simultaneous sexual partnerships, gender inequalities, and the limited distribution 
of condoms (Beyrer, 2007). 
Since the recognition of HIV as a causative of AIDS in 1983 until 2013, 78 million people 
have been infected and 39 million people have died due to HIV/AIDS (Barre-Sinoussi et al., 
1983; UNAIDS, 2016). UNAIDS (2016) estimated that in 2015, 36.7 million people were 
living with HIV and WHO estimated the worldwide mortality rate of HIV/AIDS to be 1.1 
million people in 2015 (UNAIDS, 2016). Sub-Saharan Africa is the most affected region, 
accounting for approximately 52% of people living with HIV/AIDS globally (UNAIDS, 
2016). 
In the sub-Saharan African region, South Africa (SA) has the highest HIV burden. WHO 
estimated that the number of people living with HIV in SA by the end of 2015 was 7 million 
people which increased from 5.3 million people during 2005 (UNAIDS, 2016). SA has 
12.2% HIV prevalence which is the fourth highest prevalence globally (UNAIDS, 2015). In 
comparison with high-income countries, low in-come countries have a higher mortality rate 
due to HIV/AIDS (Antiretroviral Therapy Cohort Collaboration, 2010).  
Tuberculosis is a major cause of illness and death in low-income and middle-income 
countries, especially in Africa (Glaziou et al., 2013). Findings of a study by Sonnenberg et 
al., (2005) conducted in SA in the pre-antiretroviral therapy era, revealed that TB infections 
doubled within a year following HIV infection, and the incidence increased due to increased 
number of people that are HIV positive. HIV-related TB mortality is decreasing globally 
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(Glaziou et al., 2013), but the majority of HIV-positive people in Africa die of undiagnosed 
TB (Cohen et al., 2010).  
In 2013, the WHO reported that in 2012, 11.7 million people in low-income and middle-
income countries had started antiretroviral therapy. The expanding access to antiretroviral 
therapy, as seen from the WHO projections, markedly changed the global epidemiology of 
HIV infection. The global prevalence of HIV has increased from 31 million in 2002, to 35.3 
million in 2012, due to increased access to antiretroviral therapy, thus enabling HIV-positive 
people to live longer while harbouring the virus (Zaidi et al., 2013).  
The number of new HIV infections in children decreased globally by 38% between 2009 and 
2012 (UNAIDS, 2013), due to increased access to antiretroviral therapy to prevent mother-to-
child HIV transmission. Despite this progress, there is still a gap in addressing the 
distribution and access to antiretroviral therapy between children and adults. The access is 
much lower in children than adults (UNAIDS, 2013). 
Antiretroviral Therapy Cohort Collaboration studies (2010) indicated that about 50% of all 
deaths in people on antiretroviral therapy in high-income countries are not due to AIDS, but 
were caused by non-AIDS related diseases such as cancers (23.5%), cardiovascular disease 
(15.7%), and liver disease (14.1%). Liver disease is common, mainly because of co-infection 
with hepatitis B and C, which share similar routes of transmission with HIV (Joshi et al., 
2011). 
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1.3 HIV structure, life-cycle, infectivity and pathogenicity 
HIV belongs to the Retroviridae family and the genus, Lentivirus. Lentiviruses are 
characterized by a long incubation period and their ability to infect non-dividing cells (Sierra 
et al., 2005; Tortora et al., 2010). HIV is a retrovirus, which has a positive-sense genomic 
RNA strand and uses virally encoded enzymes such as reverse transcriptase (RT) to 
synthesize a double-stranded DNA molecule which is the persisting viral genome in infected 
cells. There are two species under this genus of HIV as previously stated, HIV-1 and HIV-2.  
Infectious, mature HIV virions have a spherical shape of 100-120 nm in diameter and have a 
host derived lipid bilayer (with viral-encoded projecting gp120 proteins) surrounding the core 
of the virus formed by p17 protein molecules (matrix proteins) (Male et al., 2006; Roitt et al., 
2001; Sierra et al., 2005; Tortora et al., 2010). HIV is composed of two single-stranded, 
positive-sense RNA molecules that make up its genetic material. The RNA molecules are 
bound to p7 proteins forming a nucleocapsid. The genome together with three enzymes called 
reverse transcriptase (RT), integrase (IN) and protease (PR) and the 6 accessory proteins: Vif, 
Tat, Vpu, Vpr, Nef, and Rev are enveloped by capsid proteins p24 to form a conical capsid 
(Roitt et al., 2001). The mature HIV virion structure is depicted in (Figure 1.2). 
The HIV genome is made up of two identical 9.2 kb positive-sense, single-stranded RNA 
molecules (Sierra et al., 2005). The RNA molecules are composed of nine genes (gag, pol, 
env, tat, rev, nef, vif, vpr and vpu) which encode proteins essential in the life-cycle, 
pathogenesis and structure of HIV (Chinen and Shearer, 2002; Sierra et al., 2005) as seen in 
(Figure 1.3). The first three genes encode the structural proteins and the remaining six genes 
encode regulatory proteins to promote viral transcription, mature virion release and/or viral 
pathogenesis (Chinen and Shearer, 2002; Sierra et al., 2005).  
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Figure 1.2: Mature HIV-1 virion structure with some of the regulatory proteins. (Sierra et al., 
2005) 
 
Figure 1.3: Diagrammatical representation of the HIV-1 RNA genome. (Sierra et al., 2005) 
During an infection of the CD4+ T-cells (Figure 1.4), the virus attaches to the host cell via 
gp120/CD4 receptor interaction in the presence of a chemokine co-receptor (CCR5 or 
CXCR4). This interaction results in the fusion of the virus and the host cell. Following viral 
fusion, the virus-encoded enzyme, RT, copies the RNA genome into a double-stranded 
complimentary DNA (cDNA) which is integrated into the host genome by IN and cellular co-
factors (Male et al., 2006; Roitt et al., 2001). Once the HIV virus genome is integrated into 
the host chromosomes, there are two events that are possible: either the virus becomes 
inactive (thereby forming what is known as a provirus) and the diseased cell continues to 
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function ordinarily; or the virus becomes active and replicates to yield  108 virions/day 
which will infect other cells (Roitt et al., 2001).  
 
Figure 1.4: HIV-1 life cycle, pathogenesis and sites of action of current ARV drugs. (taken from 
Walker and colleagues, 2014)   
The various enzyme-dependent HIV lifecycle steps needed for the production of infectious 
virions, as seen from Figure 1.4, renders HIV vulnerable to potent inhibitors for each step of 
the cycle. This is the basis for the development of ARVs against HIV.  
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1.4 Highly Active Antiretroviral Therapy (HAART) 
The past three decades have seen a huge drive in the search for effective chemotherapeutic 
agents to treat HIV infection. To develop effective anti-HIV agents, one needs to fully 
understand the structure, genetics and life-cycle of the virus. Research so far has focused on 
developing agents that target specific steps in the HIV life-cycle. This is necessary because 
these steps are important in determining the infectivity and pathogenicity of the virus. 
The most significant advance in the medical management of HIV-1 infection has been the 
treatment of patients with antiviral drugs which can suppress HIV-1 replication to 
undetectable levels. The discovery of HIV-1 as the causative agent of AIDS together with an 
ever-increasing understanding of the virus replication cycle have been instrumental in 
pioneering effective antiretroviral drugs against HIV. To date, there are several Food and 
Drug Administration (FDA) approved drugs available for treatment of HIV-1 infections 
(Figure 1.5). These drugs are distributed into six distinct classes based on molecular 
mechanism and resistance profiles: nucleoside-analogue reverse transcriptase inhibitors 
(NRTIs), non–nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, 
protease inhibitors (PIs), fusion inhibitors, and co-receptor antagonists (Clavel and Hance, 
2004). So far, no inhibitors pioneered against the viral accessory proteins have been approved 
by the FDA. Inhibitors against Tat are still in clinical trials (Arts and Hazuda, 2012). 
To treat HIV, the above inhibitor drugs are used concurrently. This method of treatment is 
known as highly active antiretroviral therapy (HAART) which is defined as the use of a 
combination of the antiretroviral drugs for the treatment of HIV infection (Clavel and Hance, 
2004). Current HAART regimen is comprised of three antiretroviral drugs, in most cases 
having two nucleoside analogues and a protease inhibitor or a non-nucleoside reverse 
transcriptase inhibitor (Clavel and Hance, 2004). Alternative regimens include a boosted PI-
based regimen or an INSTI-based regimen (integrase strand transfer inhibitor). The 
combination of drugs from different classes in the treatment of HIV is effective in reducing 
drug resistance development.  
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Figure 1.5: Some of the FDA-approved ARVs for the treatment of HIV/AIDS. 
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1.4.1  Mode of action of ARVs and mechanism of drug resistance by HIV-1 
Nucleoside-analogue reverse transcriptase inhibitors (NRTIs), are pro-drug molecules that 
require phosphorylation by the cellular kinases in order to enact their antiviral function (Arts 
and Hazuda, 2012). The pro-drug molecule lacks a 3'-OH group in their sugar moiety, thus 
preventing the formation of the 3'-5' phosphodiester bond between the nucleoside 
triphosphates utilised in HIV proviral DNA synthesis, which in turn results in DNA synthesis 
termination by the reverse transcriptase enzyme (Arts and Hazuda, 2012). Resistance to 
NRTIs is usually regulated by two mechanisms: ATP-dependent pyrophosphorolysis, which 
is the removal of NRTIs from the 3'-end of the nascent chain and reversal of chain 
termination, and/or increased discrimination between the native deoxyribonucleotide 
substrate and the inhibitor (Arts and Hazuda, 2012). 
NNRTIs are non-competitive inhibitors that inhibit HIV-1 RT by binding and inducing the 
formation of a hydrophobic pocket proximal to the active site, thereby resulting in spatial 
conformational change of the substrate binding site and reduction in polymerase activity 
(Arts and Hazuda, 2012). NNRTIs resistance usually arises from amino acid substitution with 
the K103N and Y181C being the most common mutations (Arts and Hazuda, 2012). These 
mutations confer resistance to first-line ART and hence patients have to be enrolled to the 
second-line ART which is costly. 
Integrase inhibitors target the strand transfer reaction which is one of the two functions of 
integrase. The other function of integrase is to process the 3'-end of the HIV DNA for 
successful incorporation into the host genome. The mechanism of action of the inhibitors is 
through the binding of the integrase/viral DNA specific complex and then sequestration of 
the magnesium ion co-factors essential in the integrase active site (Arts and Hazuda, 2012). 
Resistance to these inhibitors is through mutation in the active site of the integrase near the 
amino acid residues that coordinate the magnesium co-factors (Arts and Hazuda, 2012). 
Protease inhibitors fall within the class of competitive inhibitors. They bind strongly to the 
active site and prevent the cleaving of gag and gag-pol polyproteins to yield mature virions. 
Resistance to these inhibitors is through the amino acid changes near the enzyme‟s active site 
which results in poor binding affinity for the inhibitor (Arts and Hazuda, 2012).  
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Entry inhibitors disrupt entry events used by HIV. HIV uses several host proteins for 
attachment, fusion and release of the virus core into the cytoplasm. CCR5 antagonists are 
allosteric inhibitors that work by binding to the hydrophobic pocket of the trans-membrane 
helices of CCR5, thereby stabilising the receptor conformation and thus the interaction with 
the V3 loop of gp120 is inhibited (Arts and Hazuda, 2012). Drug resistance to entry 
inhibitors, more especially the CCR5 antagonist, is mediated by four factors: tropism 
switching (utilisation of CXCR4 instead of CCR5), fast rate of entry of the viral core, 
utilisations of the inhibitor-bound receptor and increased affinity for the receptor (Arts and 
Hazuda, 2012). 
HIV drug resistance is influenced by high virus production and turnover (  107-108 virions 
produced per day). Furthermore, the error prone RT, introduces mutations in every virion 
produced and, hence, creating a heterogeneous virus population of quasispecies (Arts and 
Hazuda, 2012; Clavel and Hance, 2004). Although other mutations have also been found, 
including insertions, duplications and recombination; studies have shown that mutations 
introduced in every viral genome transcribed by RT are predominantly base substitutions 
(Arts and Hazuda, 2012; Clavel and Hance, 2004). 
Despite the success in the development of drugs that have revolutionized the lives of HIV 
positive patients enabling them to live with HIV for decades, a search for a cure is still on 
going. The development of new and effective antiretroviral drugs to treat HIV is crucial 
because of the fact that the virus is constantly evolving as proven by the observed mutations 
leading to drug resistance to the currently used antiretroviral chemotherapy regimens. New 
strategies under development include: gene therapy (e.g. Berlin patient) (Younai, 2013), 
targeting innate immune responses with targets including APOBEC3G, tetherin (that blocks 
viral release) and TRIMα (that destabilizes the HIV capsid and interferes with reverse 
transcription) (Ali et al., 2012; Ellegard et al., 2011; Monajemi et al., 2012; Shankar et al., 
2012; Shi et al., 2011); „LEDGF/p75‟, an integrase enzyme cofactor, whose antagonists are 
being studied for their ability to suppress HIV replication (Hu et al., 2012). Other possible 
ARV mechanisms involve the endogenously secreted antimicrobial peptides such as 
defensins, lactoferrins, secretory leukocytes protease inhibitor and Trappin-2/Elafin. These 
peptides have shown to possess strong anti-HIV properties (Ellegard et al., 2011; Shankar et 
al., 2012).  
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Other avenues include looking at natural products for a cure. This approach is inspired by the 
fact that current HAART treatment is associated with high cost, adverse effects, emergence 
of drug resistance, and the narrow spectrum of activity which has limited the therapeutic 
usefulness (Klos et al., 2009). Conversely, natural products may have better efficacy, safety 
and affordability. Several natural products, mostly of plant origin, have been shown to 
possess promising activities that could assist in the prevention of the disease. Many of these 
anti-HIV agents have other medicinal uses as well (Asres, 2005), which afford them further 
potential as novel leads for the development of new drugs that can deal with both the virus 
and the various disorders that characterize HIV/AIDS. 
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2 CHAPTER 2 
2.1 PLANTS AND THEIR USE AS TRADITIONAL MEDICINES 
Ever since the evolution of mankind, humans have relied on nature for survival. Plants in 
particular, have played a pivotal role in providing mankind with all the necessities to survive 
in an ever-changing environment.  Plants (e.g. trees and herbs) have provided our forefathers, 
and us, with food-stuffs, shelters, clothing, means of transportation (e.g. boats), fertilizers, 
flavours and fragrances, and, importantly, medicines (Gurib-Fakim, 2007).  
Plants provide people with the primary metabolites such as carbohydrates, proteins, fats and 
vitamins. Furthermore, plants produce secondary metabolites (alkaloids, phenols, terpenes 
etc.) which are essential for both humans and the plant because they form a chemical defence 
mechanism in response to infection by microorganisms, predation, insects, herbivores and 
they also play a crucial role in aiding the plant to survive and adapt to environmental changes 
(Pengelly, 2004). Secondary metabolites were considered to be useless by-products of the 
synthesis of primary metabolites. However, through the science of Pharmacognosy („„the 
study of the physical, chemical, biochemical and biological properties of drugs, drug 
substances, or potential drugs or drug substances of natural origin as well as the search for 
new drugs from natural sources‟‟) and Ethnobotany (“the study of the relationship between 
humans and plants in all its complexity”), it was observed that these products are the basis of 
the healing properties of medicinal plants. Neuwinger (1994) found that constituents with 
special properties often occur in a high concentration and sometimes with greater purity in a 
particular medicinal plant.   
The link between humans and healing plants dates back to ancient times, sometime around 
5000 years-back according to the Sumarien records (Swerdlow, 2000). However, 
archaeological records suggest even earlier use of medicinal plants (Raskin et al., 2002). 
Plants have formed the foundation of advanced traditional medicine systems, namely, 
Ayurvedic, Unani, Chinese, African & Australian and Central & South American. These 
traditional systems have provided a wealth of knowledge regarding the discovery of 
pharmaceutical products which are used nowadays (Gurib-Fakim, 2006).  
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African traditional medicine, itself, is the oldest and perhaps most diverse of all traditional 
medicine systems. African traditional medicine in its varied forms is a holistic system 
involving both body and mind. The healer typically diagnoses and treats the psychological 
basis of an illness before prescribing medicines to treat the symptoms. The Khoi-San people 
of southern Africa, nowadays considered to be the most ancient of all cultures, have an 
extraordinarily diverse materia medica (medicinal plants and other materials) which typically 
includes general tonics, fever remedies, sedatives, diuretics, laxatives and numerous wound 
healing plants (van Wyk and Wink, 2004). This is not exceptional, however, when 
considering that of the estimated 300 000 species of plants which exist throughout the world 
(Cotton, 1996), southern Africa possesses approximately 24 000 taxa of 368 families, 
including more than 10% of the world‟s vascular plant flora on less than 2.5% of the Earth‟s 
land surface (Germisthuizen and Meyer, 2003). 
Evidence also shows that the vast majority of people on this planet still rely on their 
traditional materia medica for their everyday health care needs (WHO, 2013). It is also a fact 
that one quarter of all medical prescriptions are formulations based on plant-derived 
substances or plant-derived synthetic analogues (pharmacophores). According to WHO, 80% 
of the world‟s population, primarily those of developing countries, rely on plant-derived 
medicines for their healthcare (WHO, 2011).  
Phytomedicines have been shown to be affordable, effective and safe. The latter being mainly 
because when plant medicines have been used by these traditional cultures for centuries, they 
seldom show evidence of serious side effects (Heinrich et al., 2004). It is only within the last 
few decades that research results generated have given us a much better understanding of the 
scientific rationale behind many natural remedies. 
Phytomedicines often contain a mixture of substances that have additive or even synergistic 
effects. Phytomedicines may have direct or indirect effects on several different biochemical 
pathways and receptors in the body-mind continuum that may all contribute directly and 
indirectly to restore equilibrium (van Wyk and Wink, 2004).  
2.2 The use of traditional medicine in the South African context 
In South Africa, a majority of the black population consult with traditional healers. 
Traditional healers have knowledge of the healing properties of several indigenous herbs and 
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use the leaves, roots and stems of individual herbal plants or a cocktail of different herbal 
plants to treat different diseases. 
As previously stated, SA has approximately 24 000 taxa of 368 families, including more than 
10% of the world‟s vascular plant flora (about 30 000 plant species) and of these, only 20% 
are used in traditional medicine (Cherry, 2005). Furthermore, approximately 4000 species of 
this 20% are used in traditional medicine. Only, about 350 species are the most commonly 
used and traded medicinal plants (van Wyk and Wink, 2004). This just indicates that, so far, 
we have not utilized this precious knowledge from our forefathers. Some of these plants have 
been shown to have antifungal, antibacterial, antiviral and also anti-amoebic properties 
(McGaw et al., 2000).  
The problem is that the usefulness of these traditional remedies has not been systematically 
investigated, and the country (SA) is, therefore, not in a position to benefit from this 
indigenous knowledge base. Thus, a rational scientific evaluation is needed!  
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2.3 The significance of medicinal plants in drug discovery 
One of the reasons why it is imperative to do research on traditional medicines is mainly 
because, a large portion of the world‟s population relies on plant-derived medicines for their 
primary healthcare according to WHO records. Furthermore, as stated above, a majority of 
South Africans consult with traditional healers. Lastly, it is mainly due to the fact that many 
of the drugs that are used nowadays are either plant-derived or modelled from plant-derived 
molecules as will be shown below. 
To conduct research on medicinal plants and their use by humans, it is important to look at 
the two most important scientific fields in this regard; namely, ethnobotany and 
pharmacognosy. These are interdisciplinary fields of research that look specifically at the 
empirical knowledge of indigenous people concerning medicinal substances, their potential 
health benefits and the potential toxicity risks associated with such remedies (Heinrich et al., 
2004). Through these two fields, it has been shown that many drugs that are commonly used 
today, came into use through bioscientific investigation of plants used by people throughout 
the world.  
A review article by Balunans and Kinghorn (2005) presents evidence that despite the recent 
interest in molecular modelling, combinatorial chemistry, and other synthetic chemistry 
techniques by pharmaceutical companies and funding organizations; natural products, and 
particularly medicinal plants, remain an important source of new drugs, new drug leads, and 
new chemical entities (NCEs).  
Newman and colleagues (2003), showed that during the time period between 1981 and 2002, 
natural product research accounted for approximately 48% of NCEs which medicinal 
chemists (in the pharmaceutical industry) use to generate new drugs. Furthermore, they 
showed that in the specified time period, approximately 28% of NCEs were natural products 
or natural product-derived. Again, they showed that of all the synthetic small molecule 
compounds made during this time, 20% of them were modelled based on natural product 
pharmacophores.  
Butler (2004) showed that in 2001 and 2002, approximately a quarter of the best-selling 
drugs worldwide were natural product-derived. An analysis of all drugs approved worldwide 
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between 1981 and 2006 showed that 34% of all small-molecule drugs are natural products or 
their direct semisynthetic derivatives (Zhang and Wilkinson, 2007). Furthermore, evidence 
was presented that four new drugs (Arteether, Galantamine, Nitisonone and Tiotropium) 
derived from medicinal plants were approved by the FDA and they were in the USA market. 
These drugs are used to treat malaria, Alzheimer‟s disease, tyrosinaemia and chronic 
obstructive pulmonary disease (COPD) respectively.  
Cherry (2005) declared that about 50% of the models of the Western developed drugs are 
derived from plant materials. Farnsworth et al., (1985) also showed that 25% of the 
prescribed drugs in the United States and Canada were modelled on plant-based products and 
plant metabolites are used worldwide as drugs.  
Studies by Newman and colleagues (2007), indicate that of all the approved small-molecule 
anticancer drugs (total 155), 47% are either natural products or direct semisynthetic 
derivatives of them. Similarly, the same trend of dominance by natural products is observed 
among the anti-infective small-molecules, and astonishingly more than 75% of approved 
antibacterial drugs are natural products or their semisynthetic derivatives (74 out of 98). 
Furthermore, during the period 2000–2006, approximately 50% of the approved small-
molecule drugs were still those related to natural products. This just indicates how different 
the health system we now know today would be without natural products! 
 
The benefits of using natural products in drug discovery may be related to the fact that their 
chemical structures have been biologically prevalidated by evolutionary selection which 
defines structural prerequisites for binding to proteins targets. For example, an analysis of 
over 154 000 natural products showed that the majority of them have molecular volumes 
ranging from 100 to 500 Å
3
 (Koch et al., 2005). The authors further showed that the volumes 
found in over 18 000 binding cavities of protein targets range from 300 to 800 Å
3
. Therefore, 
the average volumes of natural products correlate with the average dimensions of protein 
cavities. Of note is that protein ligands often do not fill the entire volume of a given protein 
cavity. Although many natural products from plants and microorganisms are not meant to 
bind to human proteins, many human proteins consist of the same building blocks and 
contain similar structural domains to the targets with which natural products have coevolved 
(Koch et al., 2005). This goes to show why it is important to keep looking for NCEs from 
plants rather than solely relying on synthetic chemistry to generate NCEs. 
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Studies also show that natural products have distinct structural characteristics from synthetic 
molecules. For example, when Grabowski and colleagues (2007) analysed NPs by either a 
size-independent „chemistry space filter‟ or „support-vector-machine‟ approach, NPs 
exhibited better scores of „drug-likeness‟ than synthetic compounds. Furthermore, they 
showed that NPs contain on average twice as many oxygen atoms and three times fewer 
nitrogen atoms than synthetic drug molecules. They also contain a slightly higher number of 
hydrogen-bond donors than do synthetic drugs. NPs contain approximately four times more 
chiral centres and far fewer aromatic rings, which gives NPs better selectivity when binding 
to stereo-defined sites such as those found in many protein targets.  
Some of the plant-derived drugs used today to treat various ailments are shown below in 
Figure 2.1     
VN Hlatshwayo: MSc Dissertation  
 
20 
 
O
O
OCH2CH3
H
O
O
Arteether (Malararia)
O
N
OH
O
Galantamine (Alzheimers)
NO2
CF3
OO
O
Nitosinone (Trosinaemia)
N
O
H
O
S
OH
O
S
Tiotopium (COPD)
N
N
O
NH2
HO
O
O
F
Exatecan (Cancer)
O
O
O O
OH
Calanolide A (HIV)
H3CO
H3CO
OH
OCH3
OCH3
Combretastatin (Cancer)
NH
O
O
HO
O
O
OH O
O
O
O
O
H
O OH
O
Taxol (Cancer)
O
HO
OO
HH
OHHO
HO
HO2C
Morphine-6-glucuronide (Pain)
N
H
O OH
OHO
HO
HO
HO
OH
O OH
OHO
HO
HO
OH
Myricetin (HIV) Quercetin (HIV)
 
Figure 2.1: Chemical structures of plant-derived drugs used to treat various ailments 
The evidence presented above clearly depicts why it is imperative to continue to conduct 
research in the field of natural products for drug discovery. NPs account for more drugs 
produced worldwide than chemically synthesized small molecules. Plants have yielded 
pharmaceutically active drugs due to the fact that plant-derived small-molecules have 
chemical structures that have been biologically prevalidated by evolutionary pressures to 
selectively and effectively interact with their protein targets to either inhibit or activate them.  
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2.4 Medicinal plants and HIV/AIDS  
The urgent need for new anti-HIV/AIDS drugs is of a global concern. In addition to the 
obvious economic and commercial hurdles, HIV/AIDS patients are faced with diverse 
difficulties associated with the currently approved anti-HIV drugs. Adverse effects, the 
emergence of drug resistance and the narrow spectrum of activity have limited the therapeutic 
usefulness of the various reverse transcriptase and protease inhibitors that are currently 
available on the market. However, it should be noted that ARVs have extended the life span 
of HIV-positive patients and made AIDS a manageable disease. The above-mentioned 
disadvantages associated with the use of ARVs has driven many scientists to look for new 
anti-retrovirals with better efficacy, safety and affordability. As has always been the case in 
the search for cures, natural sources offer great promise. Several natural products, mostly of 
plant origin, have been shown to possess promising activities that could assist in the 
prevention and/or betterment of the disease.     
Through scientific screening of plants, a number of medicinal plants have been reported to 
possess anti-HIV properties (Chinsembu and Hedimbi, 2010; Cos et al., 2004; Singh et al., 
2011; Yang et al., 2001). The anti-HIV properties of plant compounds are through the 
interaction or inhibition of the viral enzymes RT, PR or IN (Cos et al., 2004; Klos et al., 
2009; Singh et al., 2011; Vermani and Gard, 2002; Yang et al., 2001). For example, Klos and 
colleagues (2009) showed that ethanolic extracts of Bulbine alooides and Leonotis leonurus 
possess HIV-1 PR inhibition. Table 1 below depicts the plants used to treat HIV/AIDS. 
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Table 1: Plant-derived compounds that possess anti-HIV-1 activity and their targets   
Plant  
 
Compound  Class  Target    Reference  
Quercus rubra  
 
Cephaelis 
ipecacuanha 
Coriandrum sativum  
Hyssop officinalis  
Tryptarygium 
wilfordii  
Faicalein, quercetin, 
myricetin, baicalin 
 Psycotrines  
Coriandrin  
Caffeic acid  
Salaspermic acid 
Flavonoid  
 
Alkaloid  
Coumarin  
Tannin  
Flavonoid 
Reverse 
transcriptase 
Cowan, 1999 
 
Tan et al., 1991 
Vlietinck et al., 1998 
Houghton et al., 
1994 
 
Momordica 
charantia,  
Gelonium 
multiflorum  
 
Quercus rubra  
Thalassia 
testudinum 
MAP30, GAP31, 
DAP32, DAP30  
 
Quercetin 
Thalassiolin A, B & C 
Proteins  
 
 
Flavonoid 
 
Integrase  Wang et al., 1999 
Lee-Huang et al., 
1991 
Cowan 1999 
Rowley et al., 2002  
Rosmarinus 
officinalis  
Geum japonicum  
Ganoderma lucidum 
Carnosolic acid  
Ursolic acid 
Ganoderic acid-a 
Ganoderiol F 
Ganodermontriol 
Ganoderic acid B 
Terpenoids  
Terpenoids 
Terpenes  
Protease Vlietinck et al., 
1998 
Cowan 1999 
Yadav et al., 2009 
Coriandrum sativum  
 
Schumanniophyton 
magnificum  
Prunella  
Glycocoumarin  
Licopyranocoumarin 
Schumannificine 1  
 
Prunellin 
Coumarine  
 
Alkaloid  
 
*PS 
Adsorption  Vlietinck et al., 
1998 
Houghton et al., 
1994 
Cowan 1999  
*PS= Polysaccharides  
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No single herbal plant has been used to treat HIV patients so far; but instead herbal 
concoctions have been used. Herbalists usually use herbs that seem to have logical 
association with the AIDS disease. The herbs used are those usually used for the treatment of 
viral infections such as hepatitis B and those used for the treatment of the clinical symptoms 
of AIDS viz. wasting, diarrhoea, lymphadenopathy, skin lesions, cough, haemoptysis and 
genital ulcers (Klos et al., 2009).  
Despite all the evidence presented above, SA is still at its infancy with regards to utilizing the 
rich plant biodiversity in order to harness its benefit for human health. Thus, we have only 
scratched the surface of this wonderful resource of natural chemicals with its vast potential 
for the development of new drugs for medicinal use. This is why it is imperative to continue 
with natural product research.  
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2.5 Medicinal plants used in this study  
For the purpose of this study, six medicinal plants were investigated. The plants were 
collected from Kwa Zulu Natal (KZN). Different parts of the plants were used for extraction, 
viz. leaves, stems, bark and rhizomes. These plants are used by the traditional health 
practitioner (THP) to treat HIV positive patients. A literature review on these plants was also 
conducted so as to ascertain whether studies were conducted with regard to HIV research and 
also to evaluate if they possess antiviral and antimicrobial activity. Table 2 depicts the family, 
species name, traditional name and plant parts used in this study. Detailed information on 
each plant is given below.   
Table 2: List of plants to be evaluated for anti-HIV-1 activity in this study 
Family  Plant species  Traditional name Plant part used 
Amaryllidaceae  Clivia miniata  Mayime  Leaves and rhizomes 
Canellaceae  Warbugia salutaris  Isisbhaha Bark  
Hyacinthaceae Eucomis autumnalis  Umathunga  Bulbs  
Hyacinthaceae  Scilla natalensis,  Inguduza  Bulbs   
Malvaceae  Hibiscus surattensis 
L.  
Ucathucathu  Stems  
Solanaceae Solanum aculeastrum  Intuma  Fruits  
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2.5.1 Scilla natalensis  
Background 
This is a bulbous perennial plant with tall plumes of blue flowers. The wild squill belongs to 
the family Hyacinthaceae (hyacinth family). It has a large bulb covered with firm, hardened, 
papery brown or purplish tunics (bulb scales) (van Wyk et al., 1997). The plant is selectively 
toxic to mammals. It is said to be poisonous to livestock, mainly when the young leaves 
appear in spring. Apparently, it is toxic to humans when raw. It is reported that even the sap 
burns the skin. It is said that for any preparations to be taken internally, the plant must first be 
heated (Hutchings et al., 1996; van Wyk et al., 1997). 
Common names 
Scilla natalensis is commonly known as the Wild squill (English), Blue squill (English), Blue 
hyacinth (English), Blouberglelie (Afrikaans), Blouslangkop (Afrikaans), Inguduza (Zulu) 
(South African Department of Agriculture, Forestry and Fisheries, 2013; van Wyk et al., 
1997). 
 
Figure 2.2: Scilla natalensis flowers and bulb (Courtesy: Van Wyk et al., 1997) 
Location 
It is deciduous, growing during summer and dormant in the winter. S. natalensis is found in 
Eastern Cape, Kwa Zulu Natal, Free State, Mpumalanga provinces and also in Swaziland and 
Lesotho. S. natalensis is found in various habitats which range from sunny slopes, rocky hills, 
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cliffs, damp cliff faces, near waterfalls, moist depressions, streams and wetlands edges. It is 
usually found in groups or as solitary specimens (South African Department of Agriculture, 
2013; van Wyk et al., 1997).  
Medicinal uses 
In South Africa, the bulb is used medicinally and is one of the most popularly traded 
traditional herb items in KwaZulu-Natal. Warmed fresh bulb scales, slightly burned bulb 
scales and decoctions of the bulb are used externally as ointments for wound-healing, to treat 
sprains, fractures, boils and sores and to draw abscesses. The ash from a burnt plant, and the 
bulb in powdered form, is rubbed into cuts and scratches, and over sprains and fractures. 
Decoctions are taken as enemas for female infertility and to enhance male potency and libido. 
It is also known to be used as a purgative, a laxative, for internal tumors, and is used in 
conjunction with other ingredients in infusions taken during pregnancy to facilitate delivery 
and in treatments for chest pain and kidney troubles (Hutchings et al., 1996; South African 
Department of Agriculture, 2013; van Wyk et al., 1997).  
The plant has significant analgesic and antimicrobial activity, and has been reported to 
possess phytochemicals that have anti-inflammatory and anti-mutagenic properties 
(Hutchings et al., 1996; van Wyk et al., 1997).  
Chemical compounds 
Compounds isolated from this plant species include the following: Scillaren A, Proscillaridin 
A and Scillarenin. The latter compound has been shown to have antiviral activity (Sato et al., 
1974).   
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2.5.2 Solanum aculeastrum  
Background 
This is an evergreen perennial shrub with lobed discolorous leaves with sharp prickles found 
on the branches and it has a poisonous apple-like yellow fruit. Apple of Sodom belongs to the 
family Solanaceae.  
Common names 
Solanum aculeastrum is commonly called the Apple of Sodom, goat apple, poison apple 
(English), bitterappel, doodenappel, gifappel (Afrikaans) and intuma (Zulu) (Hutchings et al., 
1996; van Wyk et al., 1997). 
 
Figure 2.3: Solanum aculeastrum fruit (Courtesy: Van Wyk et al., 1997) 
Location 
This plant is found in various regions in Africa. In southern Africa, the plant is commonly 
found in Limpopo, Mpumalanga, Kwa Zulu Natal, Western Cape and Eastern Cape provinces 
and Swaziland (van Wyk et al., 1997). This plant appears not to be discriminative in terms of 
the area of the land it grows. The plant grows naturally in grassland, woodland and in forest 
margins. It grows in both gentle and steep slopes and also in all soil types ranging from 
sandy, clay loam and reddish-brown clay loam soil (van Wyk et al., 1997). In South Africa, 
the plant prefers regions with higher rainfall of more than 700 mm per year and is found from 
275- 1780 m altitudes.  
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Medicinal uses 
Medicinally it is used in the Zulu tradition to treat various ailments. The boiled fruit pulp 
with carefully removed seeds is used as a purgative agent. Ash from the burnt fruit is rubbed 
into scarifications over painful parts for the relief of rheumatism (Huchings et al., 1996). The 
bitter fruit is used to treat ringworms in cattle and horses and also anthrax. The Transkei 
people use the fruits decoctions to cleanse the nave of new born babies. The vhaVendas use 
the plant as an antiemetic agent (Huchings et al., 1996; van Wyk et al., 1997).  
Chemical compounds  
The plant is reported to possess Solanine which is a glycoalkaloid poison possessing 
fungicidal and pesticidal properties. The plant also possesses Tomatidine, Solasodine, 
Tolamargine, Tomatidenol and Tomatine (Hutchings et al., 1996).  
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2.5.3 Eucomis autumnalis 
Background 
This is a summer-growing deciduous bulb plant. Pineapple Flower grows in grassland, forest, 
swamps and river banks. The plant does not grow in the drier areas. It belongs to the 
Hyacinthaceae family of plants which was previously known as the Liliaceae (lily family). 
The bulbs are large (8-10 cm diameter), ovoid in shape, and give rise to a rosette of large, 
broad, soft-textured leaves (van Wyk et al., 1997).  
Common names 
This plant is commonly known as the Pineapple Flower (English), Pineapple Lily (English), 
Wildepynappel, Krulkoppie (Afrikaans) and Umathunga (Zulu).  
 
Figure 2.4: Eucomis autumnalis flowers and bulb (Courtesy: Van Wyk et al., 1997) 
Location 
Eucomis autumnalis is found in Africa, Eurasia and North America but most richly 
represented in southern Africa (van Wyk et al., 1997). In South Africa Pineapple Flower is 
found in Limpopo, Mpumalanga, Gauteng, Free State and Eastern Cape provinces (van Wyk 
et al., 1997).  
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Medicinal uses 
Although the bulb is toxic, Eucomis autumnalis is used medicinally in South Africa. 
Decoctions of the bulb in water or milk are usually administered as enemas for the treatment 
of lower backache, to assist in post-operative recovery, and to aid in healing fractures. The 
aqueous concoctions are also used for a variety of ailments, including urinary diseases, 
stomach ache, fevers, colic, flatulence, hangovers and syphilis, and to facilitate childbirth.  
E. clavata which is a subspecies of E. autumnalis, is used for the treatment of coughs and 
respiratory ailments, biliousness, lumbago, blood disorders, venereal diseases and to prevent 
premature childbirth (Hutchings et al., 1996). 
Chemical compounds 
Previous studies by Finckh and Tamm, (1970); Sidwell and Tamm, (1970) showed that the 
homoisoflavanoids are some of the chemical constituents of this plant species. These 
metabolites have recently been shown by Famuyiwa and colleagues (2013) to possess the 
anticancer, bactericidal, anti-Alpha glucosidase and antioxidant activity. Of note from these 
activities is the anti-α-glucosidase activity which has been implicated in preventing HIV 
fusion. Several compounds have been isolated from this plant species and they fall into 
different phytochemical classes. The isolated compounds include: Eucomnalin, 3,9-
dihydroeucomnalin, Autumnariol, Autumnariniol and Eucosterol.    
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2.5.4 Clivia miniata  
Background 
This is a perennial evergreen herbal plant with pseudobulbs and/or thick rootstocks belonging 
to the family Amaryllidaceae. It has dark green strap-shaped leaves that emerge from the 
underground stem (Hutchings et al., 1996). The plant produces brilliant orange flowers that 
are trumpet shaped. Flowering occurs mainly during spring around August/November periods 
and sometimes flowering also occurs at other times of the year (van Wyk et al., 1997).  
Common names  
Commonly the plant is known as Bush lily (English); Boslelie (Afrikaans); umayime (Zulu). 
 
Figure 2.5: Clivia miniata flowers and rhizomes (Courtesy: Van Wyk et al., 1997) 
Location 
Bush lily is endemic to SA. The bush lily plants seen around the world have been obtained 
from SA and breeders around the world, especially Japan, produced variants of this plant 
species. It is found naturally along the eastern region of South Africa, typically, in Kwa Zulu 
Natal, Eastern Cape, Mpumalanga provinces and also Swaziland. There is no specific habitat 
for this plant and, as such, it is found in subtropical coastal forest to valleys in high altitude 
forest. Bush lily grows in soil that is well drained and humus rich and in dappled shade area, 
often in large colonies.  
Medicinal uses 
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Medicinally, the plant is used to treat various conditions. The Zulu tribe uses the roots 
infusions to treat snake bites and to apply the infusions on the wound. It is are also taken to 
induce or facilitate childbirth, to treat fevers. The Xhosa tribe use the bulb decoctions to treat 
infertility and urinary complaints (Hutchings et al., 1996). Crude root and leaf extracts have 
been shown to possess antiviral activity against poliomyelitis virus and measles virus 
(Hutchings et al., 1996).  
Chemical compounds 
Compounds isolated from this plant include: Lycorine, Clivacetine, Clivoine, Cliviasine and 
Clividine.  
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2.5.5 Hibiscus surattensis L.  
Background 
This is an annual prostrate or climbing herbaceous plant which is characterized by having 
prickly stems with recurved prickles and the ovoid or globular shaped fruit (as seen in Figure 
2.6). The plant belongs to the family Malvaceae.  
Common names 
Commonly the plant is known as wild sour; bush sorrel (English), Liane oseille (French), 
Isigezo, Ucathucathu, Uvemvane (Zulu) (Hutchings et al., 1996). 
 
Figure 2.6: Hibiscus surattensis L. stems, leaves and flowers (Courtesy: van Wyk et al., 1997) 
This plant is distributed in KwaZulu-Natal, Limpopo and Mpumalanga provinces in South 
Africa. The habitats that provide ideal growth parameters for this plant species include 
grasslands and forest edges found in lowland and medium altitudes up to 1700 m. It grows 
well in regions with an average rainfall of 1000-1600 mm annually. Hibiscus surattensis L is 
also found in mashes, neglected fields and farms and in coastal habitats such as sand dunes. 
H. surattensis L is found on a wide variety of soil types (Hutchings et al., 1996; van Wyk et 
al., 1997).  
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Medicinal uses 
The pounded leaf and stalk lotions mixed with Warbugia salutaris and any kind of fat are 
used by the Zulus to treat penile irritations and sores. Milky liquid from the strained leaves 
and stalks are mixed with water and injected into vagina or penis for the treatment of 
discharge or sores from venereal diseases. The leaves are rich in mucilage and hence in some 
parts of Africa like, Nigeria, the plant is cooked and consumed as a soup. In Senegal, the 
plant is used as a moisturizer (Hutchings et al., 1996; van Wyk et al., 2000). 
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2.5.6 Warbugia salutaris  
Background 
This is an evergreen, slender tropical forest tree that grows up to 20 m tall. The plant has 
characteristic dark green, glossy leaves and white to greenish flowers. W. salutaris belong to 
the plant family called Canellaceae.  
Common names 
It is commonly known as pepper-bark tree (Eng.); peperbasboom (Afr.); Isibhaha (Zulu); 
manaka (Venda); shibaha (Tsonga) (Jager et al., 1996) 
 
Figure 2.7: Warbugia salutaris tree and bark (Courtesy: Van Wyk et al., 1997) 
Location 
This plant grows naturally along the east region of South Africa as far as KwaZulu-Natal, 
Eastern Cape and also it occurs in eastern and northern Gauteng province and across 
Swaziland. It also occurs in Malawi. The ideal growth habitat that allows propagation of this 
plant is forests and kloofs (van Wyk, 2008).  
Medicinal uses 
Medicinally, pepper-bark tree is used to treat several ailments by various tribes in South 
Africa and some parts of Africa. Zulus use powered bark together with a spoonful of cold 
water and Cannabis sativa leaves to treat dry coughs. Tree barks are also used as emetics and 
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purgatives for fever complaints and rheumatism. Sometimes the bark is used to treat chest 
pains such as intercostal neuralgia. The powered bark mixed with fat is used to treat penile 
irritation, venereal diseases. Lotions prepared by mixing Hibiscus surratensis with the 
pounded leaves with stalks are applied to the penis in cases of inflammation of the urethra, 
sores and other irritations. In West Africa, the bark and the roots are used to treat influenza, 
fevers and gastro-intestinal disorders (Hutchings et al., 1996).  
Chemical compounds 
The bark is reported to have tannins, drimane sesquitepenoids and some alkaloids with 
antimicrobial activity (Hutchings et al., 1996). Warburganal, polyoidal, salutarisolide, 
muzigadial, ugandensidial, isopolygodial, mukaadial and mannitol are some of the 
compounds isolated from this plant (Van Wyk et al., 2000).  
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Rationale 
In South Africa, the anti-HIV-1 activity of various indigenous plants has not been studied 
extensively. Most of the work has focused on anti-cancer activity with less attention given to 
infectious diseases. South Africa, to date, is faced with a high HIV prevalence and incidence 
rates that presents issues with ensuring that all individuals in need of HAART treatment 
receive it. Furthermore, even people who have access to HAART are still faced with toxic 
side effects from drugs used for treatment and viral resistance to this treatment which renders 
it less efficacious. 
These challenges justify the need for a continued search for new drug candidates with better 
activities such as low toxicity and affordability. It has been documented that most of the 
African and Asian countries still rely on traditional medicines to treat various ailments 
including infectious diseases like, HIV. There are fewer side effects that have been 
documented with regards to using traditional medicines. Furthermore, it has been shown that 
plant-derived small molecules exhibit better scores of „drug-likeness‟ than synthetic 
compounds. Plant-derived NCEs have provided scaffolds for a majority of FDA approved 
drugs for treating various conditions including HIV and cancer. Also, they have chemical 
structures that have been biologically prevalidated by evolutionary selection for binding with 
protein targets. Plant-derived compounds have more chiral centers and far fewer aromatic 
rings, which gives NPs better selectivity when binding to stereo-defined protein sites 
compare to synthetic drugs. The above-mentioned drug properties are crucial in drug 
discovery because they ensure drug flexibility, specificity and reduce the drug resistance 
profile of a pathogen targeted.  
Hence, the aim of this study is to identify, screen, phytochemically characterize and isolate 
bioactive compound(s) from a concoction presented by traditional herbalists suggesting that 
“a cocktail of these six plants: Clivia miniata, Warbugia salutaris, Eucomis autumnalis, 
Scilla natalensis, Hibiscus surattensis L. induces anti-HIV proliferation in HIV-infected 
individuals‟‟. However, this has never been tested or validated scientifically, thus the interest 
of this particular study in investigating the claimed hypothesis.  
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Aim 
The study is aimed at determining the anti-HIV-1 activity of a South African herbal 
concoction and characterization of the potential bioactive compound(s) therein.  
 
Objectives 
 To determine the toxicity of the crude extracts and compounds  
 Determine HIV viral inhibition by the plant extracts and isolated compounds using 
pseudovirion infection TZM-b1 assay   
 Evaluate whether the extracts can inhibit HIV-1 reverse transcriptase and protease 
activities   
 Phytochemical profiling of the herbal mixture extracts  
 Isolation of major phytochemical compounds from the herbal mixture  
 Structure elucidation and characterization of potential bioactive compound(s)  
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3 CHAPTER 3 
OVERVIEW OF THE METHODS AND MATERIALS 
Phytochemistry studies on medicinal plants are important because they afford a 
phytochemical profile of the plant extract. Through phytochemical profiling of the plant 
extracts, therapeutic compounds can be identified which can justify the use of that plant by 
traditional health practitioners (THPs) to treat various ailments. Phytochemical studies also 
play an important role in modern drug discovery as the characterized isolated compounds can 
be used as drug leads. Plant-derived compounds can be chemically modified to enhance 
bioactivity, bioavailability and reduce toxicity during the development of novel drugs.   
In this study, the extraction procedures that were followed are based on those used by the 
traditional health practitioners and the scientifically accepted extraction procedures (i.e. using 
organic solvents) for standardization and comparison of the actives present in the different 
preparations.  
Therefore, this chapter focuses on the materials and methods used in this study, such as the 
following:  
 preparation of dried plant material and preparation of extracts   
 chemical profiling of extracts using Ultra-Pressure Liquid Chromatography-Mass 
Spectrometry (UPLC-MS)  
 isolation, purification and identification of compound(s)  
 screening of extracts and isolated compounds for toxicity  
 screening the extracts and isolated compounds against HIV enzymes: RT, PR, and for 
inhibition of HIV entry into cells    
 
The following studies were conducted in the Biosciences Unit of the Council for Scientific 
and Industrial Research (CSIR) based in Pretoria. 
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3.1  PLANT COLLECTION 
The ethnobotanical method was used for the collection of plant material used in this study. 
This method relies on the knowledge and use of the medicinal plants by local, indigenous 
people and, in this case, traditional health practitioners. Plants were collected from Kwa Zulu 
Natal (KZN) province in South Africa (Table 3). 
Table 3. The plant species used in this study and their location within South Africa. 
Plant species  Location  GPS coordinates  
Clivia miniata  Ngwavuma (KZN) 27⁰07'55''S; 31⁰59'39.9''E 
Eucomis autumnalis  Bergville (KZN) 28⁰44'0'' S; 29⁰22'0'' E 
Hibiscus surratensis L.  Mondlo (KZN) 27⁰58'58.76'' S; 30⁰43'3.68'' E 
Scilla natalensis  Bergville (KZN) 28⁰44'0'' S; 29⁰22'0'' E 
Solanum aculeastrum  Bergville (KZN) 28⁰44'0'' S; 29⁰22'0'' E 
Warbugia salutaris  Ngwavuma (KZN) 27⁰07'55''S; 31⁰59'39.9''E  
 
Harvested plants were washed with distilled water until no foreign object was observed and 
damaged leaves were removed so as to reduce contamination and false positive results in 
biological screening studies. The plant material was oven dried at 30–60 °C. The drying 
conditions such as temperature and time (days) varied from plant to plant due to the different 
plant parts used. Dried material was pulverized and stored at room temperature (25 °C) prior 
to extraction.  
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3.2 PLANT EXTRACTION 
3.2.1 Maceration  
The principle of the extraction method used in this study  
This is basically the extraction of phytochemicals through soaking the crushed plant material 
in an organic solvent such as methanol, ethanol, chloroform, dichloromethane etc. or non-
organic solvent such as water at a particular temperature for a defined period of time. 
Sometimes a mixture of the organic solvents is used for extraction of phytochemicals (e.g. 
dichloromethane: methanol). Maceration according to Raman & Houghton (1998) “is the 
extraction of phytochemicals or other chemicals involving bringing the solid material to be 
extracted (that has been thoroughly dried) into contact with the extraction solvent for a period 
of time, followed by separation of the solution from the solid debris”. This technique exploits 
the polarity principle of chemicals (i.e. “Like dissolves like”). Depending on the type 
(polarity) of chemical targeted for a particular study, different organic solvents with different 
polarity can be used to extract compounds that are either polar or non-polar. One of the 
advantages of this method is that compounds which degrade at elevated temperatures are also 
extracted and not degraded.  This method was used in this study to prepare organic extracts 
for all six plants and also for the herbal mixture.  
For extraction with water, heat is often required so as to maximize extraction. This method is 
often used by traditional healers to prepare decoctions which are given to their patients. In 
this extraction method, dried plant material is placed in pure distilled water and then boiled at 
a defined temperature and duration (as specified by the traditional healer). To ensure even 
and controlled temperature conditions, a heating mantle, water bath or oil bath can be used. 
The preparation of aqueous extracts for all six individual plants and the herbal decoction used 
in this study, was done through the use of an oil bath whereby the soaked solution was boiled 
using an oil bath.  This method was chosen over the water bath method because the dried 
plant material had to boil at 98-100 ⁰C similar to that used by the traditional health 
practitioner. A water bath would, therefore, not be appropriate since water boils at 100 
⁰
C and 
would, therefore, evaporate off over time.              
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Preparation of aqueous extracts 
Dry powdered plant material (100 g) of each plant was used in the preparation of the herbal 
decoction. The dried, ground plant material of six plants were combined and then added to 6 
L of high-purity dH2O and boiled at a temperature of 98 ⁰C for 1 hour while stirring using a 
3-neck round-bottom flask half submerged in an oil bath. The temperature of the boiling 
solution was monitored with a thermometer. After cooling, the mixture was filtered using a 
sterile white cloth and the resulting filtrate was then further filtered by using Whatman 
number 1 filter paper with a pore size of 11 µm (Sigma-Aldrich, USA).  
Water extracts of the six individual plants were also prepared following the aforementioned 
procedure using 30 g of plant material and 350 mL high-purity dH2O. Following filtration, 
the filtrate was dried and concentrated overnight using a Genevac speed vacuum concentrator 
(United Scientific, USA) The following day the extracts were further dried under reduced 
pressure using a vacuum pump. The extracts were stored at -20 ⁰C until it was required.  
Preparation of organic extracts 
The organic solvent used for extraction in this study was absolute ethanol (Sigma-Aldrich, 
USA). The choice of solvent was motivated by the fact that it has low toxicity, evaporates off 
easily, has antimicrobial activity, does not cause complexation or dissociation of the extract, 
it extracts higher amounts of polyphenols, bioactive flavonoids as well as aromatic and 
organic compounds (Lapornik et al., 2005; Bimakr et al., 2010; Wang et al., 2010 & Cowan 
et al., 1999).  
The ethanolic herbal extract was prepared by mixing 100 g of the individual dried plant 
material resulting in 600 g dried herbal plant material which was then macerated with 6 L of 
absolute ethanol overnight at 28 ⁰C in a shaker at 180 rpm. Following maceration, the extract 
was filtered with 11 µm Whatman filter paper (Sigma-Aldrich, USA). The resulting filtrate 
was concentrated by evaporating off the organic solvent using the Buchi Rotavapor R-II 
(Buchi Labortechnik AG, Switzerland) at a temperature of 64 ⁰C. Furthermore, each of the 
extracts was further dried under reduced pressure using compressed air at room temperature 
for 24 hours.  
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The extracts of the six individual plants were prepared by following the aforementioned 
procedure but using 100 g plant material in a 1 L absolute ethanol instead. Extracts to be 
screened for biological activity were stored at -20 ⁰C until required.  
3.3 LIQUID-LIQUID PARTITIONING 
The principle of liquid-liquid (LL) partitioning  
This method entails using two solvents with different polarity (polar: nonpolar). The main 
principle of this method is that the solubility of uncharged substances in any phase at a fixed 
temperature is dependent on its similarity in polarity to the liquid phase (i.e. “like dissolves 
like”). In this method, a dry extract is solubilized and then mixed with another solvent (that 
has a different polarity index to the solvent used for solubilizing the extract) in a separating 
funnel and shaken vigorously. This mixing of different solvents results in the formation of 
two layers (usually called phases) that have different chemical composition. Polar compounds 
in the extract will be distributed to the polar phase and nonpolar compounds to the nonpolar 
phase. This method is suitable for concentrating and “cleaning-up” the extract, i.e. removal of 
nonessential phytochemicals such as chlorophyll and nonpolar compounds when targeting 
polar compounds for a particular study.   
Preparation of the “clean” extract used in isolation of potential bioactive compounds 
Liquid-liquid partitioning was employed in this study to separate the extracts based on 
polarities and to obtain a higher concentration of polar compounds. The ethanolic organic 
extract was first dissolved in methanol/water (9:1) and then partitioned with hexane three 
times using a separating funnel. The methanol/water polar layer which has more polar 
phytochemicals present in it was collected and concentrated under reduced pressure by using 
a Buchi Rotavapor R-II (Buchi Labortechnik AG, Switzerland) at 60 ⁰C. The resulting 
concentrated extract was further dried under stream of air using compressed air in a fume 
hood overnight at room temperature. This extract was used for the isolation of potential 
bioactive compounds.  
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3.4 CHROMATOGRAPHY  
Chromatography is used in the separation of individual constituents within a sample on the 
basis of their physical properties, e.g. molecular size, shape, charge, volatility, solubility 
and/or adsorptivity. Different chromatographic systems are characterized by the form of 
chromatographic bed, nature of the mobile and stationary phases and the method of 
separation employed (Reed et al., 2007).       
3.4.1 Thin layer chromatography (TLC)  
The principle of TLC  
Chromatography is a technique whereby a sample mixture is separated on the basis of its 
physiochemical differences e.g. molecular size, shape, charge, volatility, solubility and 
adsorptivity. A complete chromatographic system is comprised of a stationary phase, mobile 
phase, delivery system and detection system.  The types of stationary phase adsorbents most 
commonly used in chromatography are silica gel (SiO2 x H2O) and alumina (Al2O3 x H2O). 
Both of these adsorbents are polar, but, alumina is more so. A mobile phase can either be 
liquid or gas and these carry the sample through the stationary phase and by eluting the 
sample from the chromatographic bed. Sample separation is through the interaction of the 
sample with the stationary phase, the stronger the interactions, the more time the sample 
spends on the stationary phase and, hence, it will be eluted later or have a smaller relative 
frontal mobility value (Rf) in a TLC separation. The inverse applies when the sample has 
weak interactions with the stationary phase. 
  
TLC is a sensitive, fast, simple, and inexpensive analytical technique. TLC involves spotting 
the sample to be analyzed near one end of a sheet of glass or aluminum that is coated with a 
thin layer of an adsorbent. The sheet, which can be the cut into various sizes, is placed on end 
in a glass tank containing a shallow layer of solvent. As the solvent rises up the stationary 
phase by capillary action, differential partitioning occurs between the components of the 
sample mixture in the stationary adsorbent phase (Fried and Sherma, 1996; Houghton and 
Raman, 1998).  
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Some common uses of TLC:  
1. To determine the number of components in a mixture. 
2. To determine the identity of two substances. 
3. To monitor the progress of a reaction. 
4. To determine the effectiveness of a purification. 
5. To determine the appropriate conditions for a column chromatographic separation. 
6. To monitor column chromatography (Fried and Sherma, 1996) 
A large number of spray reagents have been produced which, when sprayed onto separated 
bands/spots on the TLC sheet, results in the formation of different colors from colorless 
substances. Some of the spray reagents are very specific, but many others will react with 
various compounds. Therefore, these spray reagents can be used for the detection and 
identification of particular compound classes present within the sample mixture. (Houghton 
and Raman, 1998).  
 
Application of TLC in this study 
We first used thin layer chromatography (TLC) to obtain an appropriate solvent system for 
the isolation of compounds using vacuum liquid chromatography and column 
chromatography. This was done to select the type/class of compounds that was going to be 
isolated and also to determine the chemical profile of the extracts (i.e. detect the major 
compound types in the individual extracts). Natural products have both fluorescent and 
quenching properties. These properties are exploited in the isolation of phytochemicals by 
using TLC and viewing the separated phytochemicals under UV light. 
Aluminum backed TLC plates that pre-coated with silica gel (Merck, SIL G-25 UV 254, 20 
cm x 20 cm) were used to obtain the profiles of the individual plant extracts following 
separation. These plates have a fluorescent agent incorporated into the silica stationary phase 
so as to give a uniform, brightly colored background when exposed to UV light. Visualization 
of the separated phytochemicals was done under UV light (254 and 366 nm,) short and long 
wavelengths respectively and spraying with vanillin-H2SO4 reagent, followed by baking the 
TLC plate at 100OC for 1 minute. The use of vanillin-H2SO4 reagent was due to the fact that 
it is not specific for a particular class of compounds like other chromogenic sprays. Sulfuric 
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acid (H2SO4) oxidizes many compounds and hence the vanillin-H2SO4 is the ideal reagent to 
use for getting a profile of the extracts prior to extraction.  
In the case of isolating alkaloids, Dragendorff chromogenic reagent was used which is 
specific for alkaloids.   
3.4.2  Vacuum liquid column chromatography (VLC) 
Principle of VLC 
This is a form of column chromatography that is useful for obtaining fractions rapidly and 
saves time. It is similar to column chromatography with the exception of using a Büchner 
funnel (which is relatively short as a column), a Büchner flask for collecting the eluents and 
reduced pressure to facilitate the mobile phase elution from the column. The principle is 
based on separating a sample mixture applied onto a tube (column) that is tightly packed with 
porous particles and allowed to permeate the column under reduced pressure in the presence 
of a suitable mobile phase solvent.  Some variations of VLC include a separating funnel in 
place of the Büchner flask so as to prevent the disassembling of the apparatus during the 
collection of eluent aliquots.  
Fractionation of crude extracts 
The process of isolating compounds from the crude extract began by fractionating the crude 
extract. Fractionation of the crude ethanolic herbal concoction extract was achieved by using 
VLC.  
A column was dry packed with silica gel 60, (35-75 µm diameter size, Merk, Germany). The 
packing was done under vacuum to achieve maximum packing density. The solvent was 
poured and sucked dry under vacuum (reduced pressure) so as to saturate the column prior to 
the actual fractionation procedure. The sample was loaded in the form of a dry slurry and the 
vacuum reapplied to settle the sample. Cotton wool was then placed on top of the dry slurry 
to prevent disruption of the slurry during addition of the eluting solvent. The column was 
then eluted with an appropriate solvent mixture (or solvent of increasing polarity). In each 
step, the column was allowed to dry completely and be solvent free. Fractions of 200 ml were 
collected and were dried at ambient temperature overnight.  
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3.4.3 Dereplication of ethanol organic extract  
Dereplication refers to the removal of unwanted compounds within extracts which, when 
present, might interfere with the bioassay system and give false positives. The material to be 
removed from the extracts fall in either of two categories: 
1. those present in large quantities which may render isolation difficult and may also 
interfere with the test assay system. Chlorophyll and carotene pigments fall into this 
category especially if the extract was prepared from leaves since these have higher 
quantities of this material. 
2. Substances that interact non-specifically with a wide range of enzyme systems. The most 
notorious group in this class are the polyphenolic substances known as tannins. These 
compounds form crosslinks with many protein targets, and thus, inhibit biological 
systems. These compounds should always be removed in drug discovery research that is 
focused on discovering novel drug leads.  
Studies by Cardellina et al., (1993) at the NIH indicated that tannins present in plant extracts 
are responsible for false positive results especially in HIV studies on medicinal plants. Thus, 
in the present study, tannins were removed from the herbal concoction to avoid getting false 
positive results. Tannins were removed by using a protocol outlined by Raman and 
Houghton (1998) which was slightly modified. Polyvinylpolypyrrolidone (PVPP) (Sigma-
Aldrich, USA) was utilized instead of polyamide resins. A VLC column was packed with 
PVPP instead of silica gel, saturated with dH2O for 30 mins and then allowed to elute prior 
to loading the herbal concoction sample mixture to be dereplicated. The sample mixture was 
dissolved in a minimum volume of methanol and applied to the column. The column was 
eluted with absolute HPLC-grade methanol until the eluent was clear (Raman and Houghton, 
1998).       
3.4.4  Column chromatography (CC) 
Principle of CC 
This is the oldest form of chromatography that is useful for obtaining extract fractions and 
purifying sample mixtures. Here, a column is packed with a solid stationary phase (such as 
silica gel), a   sample mixture is then applied to the column and a mobile phase is allowed to 
move down the column under gravity. The contents in the sample mixture will move down 
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the column with the mobile phase but at different rates due to their physicochemical 
interactions with the stationary phase. The separated sample mixture constituents are 
collected as aliquots. The separation of the sample mixture can be achieved by using either a 
gradient or an isocratic mobile phase whereby, in the latter case, there is no altering of the 
mobile phase mixture composition. The stepwise gradient elution on the other hand, is 
characterized by altering the composition of the mobile phase by either increasing or 
decreasing the polarity of the solvent system. Major drawbacks of this method are that it is 
time-consuming and results in poorly resolved „bands‟ which require repeated purification 
steps to achieve good resolution. 
Isolation of major compounds from VLC fractionated extracts      
This method was employed in order to purify the fractions obtained from VLC and to isolate 
phytochemicals. Various column sizes were used depending on the amount of sample 
available and the purification stage. The separation of fractions was generally carried out on a 
column using silica Gel-60 (35-70 µm diameter) under gravity. Equal volumes of 100 ml 
were collected and dried overnight at ambient temperature. The fractions were spotted onto a 
TLC plate to determine whether they could be combined; thus, concentrating the major 
compounds in those fractions and also to determine whether another round of purification by 
CC was required or not.     
3.4.5 Preparative thin layer chromatography (prep-TLC) 
The principle of prep-TLC 
This technique is similar to the normal TLC technique. The only difference is the amount of 
sample applied, the way it is applied and the visualization/detection method. A thin 
horizontal band of sample not greater than 40 mg is applied at the base of the plate in prep-
TLC as compared to applying a spot on a normal TLC plate. A non-destructive method 
should be used (i.e. avoid chromogenic spray reagents) for visualization of the isolated 
compounds. If there is no suitable non-destructive method then one can use the spray reagent 
but only spraying the edge of the plate while approximately 90% of the plate is covered and 
not exposed to the reagent. The plate is developed much like the way a TLC plate is 
developed. This technique is only applied at the end of purification, prior to structure 
elucidation and/or biological testing.  
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Application of prep-TLC for the isolation of compounds 
Isolation and purification of compounds which were visible under UV light and also reactive 
to the vanillin-H2SO4 reagent was achieved by using this technique. This method involves 
applying a semi-pure sample in the form of a band approximately 1.5- 2 cm from the bottom 
of the plate. The plate is then developed in a solvent system which has been shown to 
separate the components present in the semi-pure sample.   
Glass plates pre-coated with silica gel (Merck, SIL G-25 UV 254, 20 cm x 20 cm) were used 
for isolation of compounds. The samples were loaded onto the plates by using a Pasteur 
pipette. The plates were then developed in a chromatography tank with the appropriate 
solvent system and the compounds of interest were detected under UV light and by vanillin-
H2SO4 or Dragendorff reagent. The bands were then scraped off the plate and dissolved in a 
solvent system used for the separation and then filtered to remove the silica gel from the 
filtrate containing compounds of interest. Furthermore, the silica gel was washed with 
methanol to maximize the recovery of the isolated compounds. The solvent used for 
recovering the isolated compounds was evaporated overnight at ambient temperature. 
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Figure 3.1: Schematic representation of the fractionation of the ethanol herbal 
concoction. 
The flow chart shows the step-by-step fractionation, the conditions, the solvent systems for 
the different chromatographic methods used to get the various fractions. chloroform (CHCl3), 
hexane (Hex), methanol (MeOH), ethyl acetate (EtOAc) were used in different ratios (v/v) in 
the solvent systems.  
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3.4.6 Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) 
The principle of UPLC-MS 
UPLC is a highly developed powerful analytical technique with a wide range of variations 
mainly used as preparative tools and to obtain chemical fingerprints of plant material (Holme 
and Peck, 1998). UPLC is a development of column chromatography and allows for 
improved resolution compared to its counterparts, such as, HPLC. UPLC columns are packed 
with small sized particles with a narrow size distribution. Flow rate and column dimensions 
can be adjusted to minimize band broadening. The required pressures are supplied by pumps 
that can withstand the types of chemicals present.   
In addition to the normal phase columns, there are also reverse phase (RP) columns. The 
latter normally involves the use of a polar solvent (water, methanol, acetonitrile etc.) and a 
nonpolar surface. RP-UPLC is the method of choice for larger non-volatile molecules.    
The commonly used detector (a UV detector) in HPLC and UPLC systems not only places 
constraints on the solvents that can be used but is also limited to absorbing compounds. 
Refractive index detectors, although considered "universal", cannot easily be used with 
solvent gradients. Recently, the evaporative light-scattering detector has emerged as a 
universal detector. UPLC has been coupled to mass spectrometry to enhance its performance.    
 
Coupling of a mass spectrometer (MS) and Quadrupole Time-of-Flight (Q-TOF) analyzer to 
UPLC results in a faster analysis time, accurate determination of elemental composition of 
the molecule, accurate molecular weight determination, and identification of the separated 
molecules. This technique has been useful in the drug development process. MS alone has 
been used for lead compound discovery, structural analysis, synthetic development, 
combinatorial chemistry, pharmacokinetics and drug metabolism (Pavia et al., 2009).  
 
Application of UPLC-QTOF-MS for plant extract profiling and accurate mass determination 
of isolated compounds 
 
UPLC-QTOF-MS was used for plant metabolite profiling, and accurate mass determination 
of the isolated compounds. To obtain the phytochemical profile of the plant extracts and the 
herbal concoctions, the chromatographic separation was done by utilizing a Waters BEH C8 
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column with the dimensions (150 mm × 2.1 mm, 1.7 µm) at a constant column temperature of 
60 °C. A binary mobile phase solvent system was used which was a mixture of acetonitrile 
(eluent B), water (eluent A), and 0.1% formic acid (Romil Chemistry, UK). The initial 
conditions were 80 :20 (A:B) at a flow rate of 0.4 ml min
-1
 and kept constant for 1 min. A 
stepwise gradient separation method was used to change the chromatographic separation 
conditions. The overall runtime was 20 min and the injection volume was 5 μl. The PDA 
detector was scanned between 200 and 500 nm (1.2 nm resolution) and set for collecting 20 
spectra s
-1
. Following the chromatographic separation and detection by UPLC-PDA 
detection, Q-TOF was conducted so as to get the masses of the separated molecules within 
the extracts. For detailed conditions for MS-QTOF refer to section 3.6. Table 4 below depicts 
a stepwise gradient elution timetable used for the chromatographic separation of the 
molecules within the extracts. 
Table 4: Stepwise gradient elution timetable profile 
Time   
(minutes) 
Flow rate  
(ml min
-1
) 
% A  
(H2O):0.1% FA
* 
% B  
(Acetonitrile):0.1% 
FA
* 
Initial 0.4 80 20 
1.00 0.4 80 20 
15.00 0.4 20 80 
15.10 0.4 5 95 
17.00 0.4 5 95 
18.00 0.4 80 20 
20.00 0.4 80 20 
  *FA= formic acid 
3.5 Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear Magnetic Resonance (NMR) spectroscopy is the study of the interaction of 
electromagnetic radiation (EMR) with matter. NMR spectroscopy is specifically concerned 
with the interaction of radio frequency (RF) of EMR with unpaired nuclear spins of atoms in 
the presence of a strong external applied magnetic field. It is fundamental in organic, 
inorganic and analytical chemistry since it is used for the investigation of molecular 
structures and dynamics. NMR allows chemists to study 3D structures of bio-molecules at 
high resolution. It allows the detection of bio-molecule‟s atomic nuclei and deduction of the 
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chemical environment the nuclei are in, within the molecule, thus, providing information 
regarding the structural dynamics.  It is routinely used for chemical structure elucidation of 
simple molecules using simple one-dimensional technique (1D-NMR) and complex two-
dimensional NMR (2D-NMR). Two-dimensional techniques (2D-NMR) are used to 
determine the structure of more complicated molecules (Pretsch et al., 1977; Kumar et al., 
2013) such as natural products compounds.   
3.5.1 1D-Proton NMR (1H-NMR)  
The principle  
Proton NMR is both a qualitative and quantitative technique used for studying different 
protons in a compound under study. A 
1
H-NMR experiment involves exposing hydrogen 
nuclei to an applied magnetic field to generate two spin states of unequal energy. The low 
energy spin state nuclei absorb RF energy to facilitate changing the orientation of the spin 
state with respect to the applied magnetic field. As this happens, signals arising from 
absorption of RF as a function of intensity against frequency (chemical shift) are plotted to 
offer a proton spectrum (Kumar et al 2013).  
The 
1
H-NMR plot gives information regarding the area under the peak which is crucial in 
determining the number of protons present in the molecule. It gives the position of the signals 
(the chemical shift, δ) which reveals information regarding the chemical and electronic 
environment of the protons. And lastly, it provides the splitting pattern of the protons which 
is used to determine the number of neighboring (vicinal or geminal) protons (Derome, 1987; 
Ernst, 1987; Abraham et al., 1988; Silverstein et al., 2005; Kumar et al., 2013).  
Structure determination of the isolated compounds 
1
H-NMR was used to obtain the proton spectrum which was crucial in evaluating the purity 
of the isolated compounds, data regarding the number of protons, splitting pattern and the 
type of protons present in the isolated compounds. All 
1
H-NMR experiments were performed 
on either the Varian 600 MHz or 400 MHz spectrophotometer at the CSIR. All NMR spectra 
were recorded at 30 °C and the chemical shifts were recorded in parts per million (ppm) 
frequency referenced to the solvent shift. Coupling constants (J-values) are calculated as 
observed in the 
1
H-NMR spectrum. Deuterated methanol (CD3OD) was used for polar 
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compounds and deuterated chloroform (CDCl3) was used for semi-polar and/or non-polar 
compounds. 
3.5.2  1D-Carbon NMR (13C-NMR)  
The principle  
Similar to proton NMR, carbon NMR involves exposing carbon nuclei (
13
C) to the applied 
magnetic field to generate two spin states of unequal energy. The low energy spin state nuclei 
absorb RF energy to facilitate changing the orientation spin state with respect to the applied 
magnetic field. As this happens, signals arising from the absorption of RF as a function of 
intensity against frequency (chemical shift) are plotted to obtain a carbon spectrum. The 
signals in 
13
C-NMR experiments normally appear as singlets because of the decoupling of the 
attached protons. Different techniques of recording of the 1D carbon NMR experiments have 
been developed so that it is possible to differentiate between the various types of carbons; 
such as, primary, secondary, tertiary and quaternary from the 1D 
13
C-NMR plot. The range of 
the chemical shift values differs between the 
1
H (normally 0-10 ppm) and 
13
C NMR 
(normally 0-200 ppm) because of the two nuclei having different numbers of electrons 
around their corresponding nuclei as well as different electronic configurations (Derome, 
1987; Ernst, 1987; Abraham et al., 1988; Silverstein et al., 2005).  
Determination of the carbon backbone of the isolated compounds 
13
C-NMR experiments were conducted to verify the purity of the isolated compounds, (as 
seen in the proton spectrum), to identify the number of carbons and also the type of carbons 
present in the isolated compounds. All 
13
C-NMR experiments of the isolated compounds 
were done on either the Varian 600 MHz or 400 MHz spectrophotometer. All NMR spectra 
were recorded at 30 °C and the chemical shifts were recorded in ppm frequency referenced to 
the solvent shift. Deuterated methanol (CD3OD) was used for polar compounds and 
deuterated chloroform (CDCl3) was used for semi-polar and/or non-polar compounds.  
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3.6 High-Resolution Time-Of-Flight Mass Spectrometry (HR-TOF-MS) 
Principle of mass spectrometry 
Mass spectrometry is an analytical technique that involves generating charged particles (ions) 
from molecules of the analyte. The generated ions are analyzed to provide information about 
the molecular weight of the compound, the elemental composition and its chemical structure.  
There are many types of mass spectrometers and different sample introduction techniques 
which allow a wide range of samples to be analyzed. All mass spectrometers consist of three 
distinct regions that can be described as the ionizer, the ion analyzer, and the detector. The 
variations of MS are mainly due to the differences in the type of ionizer and ion analyzer they 
are coupled to. These analyzers have different properties and hence the choice of a particular 
ionizer and ion analyzer is governed by the type of chemical analysis that is required (i.e. 
evaluation of non-volatile or volatile compounds and/or exact mass or a rough molecular 
mass estimate of the compound). Some of the widely-used ionizers include Electron Impact 
(EI), Chemical Ionization (CI) and Electrospray Ionization (ESI). The ion analyzers include 
Quadrupole Time-of-Flight (Q-TOF) and Ion Cyclotron Resonance (ICR). Q-TOF allows for 
a more accurate mass analysis (Snyder et al., 1979).  
Application of HRTOF-MS  
This method was used to determine the molecular mass of the isolated compounds. HR-
QTOF-MS provides accurate mass of the compounds to four decimal places which results in 
a decreased probability of misidentifying a compound. The conditions for MS-QTOF were as 
follows: SYNAPT G1 High Definition Mass Spectrometer operating in electrospray 
ionization (ESI) mode to detect the compounds of interest. Leucine enkephalin (50 pg ml
-1
) 
was used as reference calibrant to obtain typical mass accuracies between (556.2771 / 
554.2615 Da). The MS was operated in both positive and negative ionization modes (ESI+ 
and ESI-) with a capillary voltage of 2.5 kV, sample cone voltage of 30 V, extraction cone 
voltage of 4 V. The scan time was 0.1 s covering the m/z range of 100 to 1,000 Da. The 
source temperature was 120 °C and the desolvation temperature was set at 450 °C. Nitrogen 
gas was used as the nebulization gas at a flow rate of 800 L h
−1
. The software used to control 
the hyphenated system and perform all data analysis was MassLynx 4.1 (SCN 704).  
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3.7 BIOLOGICAL ASSAYS  
The following studies were conducted at the National Institute of Communicable Diseases 
(NICD), a division of the National Health Laboratories Services (NHLS) in Sandringham. 
3.7.1 Cell lines  
HEK293T   
Human HEK293T cell line (AIDS Reagent Program NIH, USA) which was originally known 
as 293tsA1609neo, is a highly transfectable derivative of human embryonic kidney 293 cells 
(HEK293), which contains the SV40 T-antigen (DuBridge et al., 1987). This cell line is 
competent to replicate vectors carrying the SV40 region of replication. It gives high titres 
when used to produce retroviruses. It has been widely used for retroviral production, gene 
expression and protein production (NIH AIDS Reagent Program). 
TZM-bl cell line 
The TZM-bl cell line is a derivative of the HeLa cell line (AIDS Reagent Program NIH, 
USA). TZM-bl is a CXCR4 positive cell line which is genetically engineered to express both 
the CCR5 chemokine co-receptor and CD4 receptor. The cells are also engineered to express 
the two reporter genes, Luciferase and β-galactosidase, which are both under the control of an 
HIV-1 promoter. The TZM-b1 cells are highly susceptible to infection with various HIV-1 
isolates and SIV and SHIV strains (Montefiori, 2005).  
3.7.2 Tissue Culture  
Cells were grown and maintained in 75 cm
2
 tissue culture flasks (T-75) (Greiner, Germany) 
with Dulbecco‟s modified Eagle‟s medium (DMEM) growth medium (Gibco, USA) 
supplemented with 10% FBS (fetal bovine serum) (HyClone, USA). The media was further 
supplemented with final concentrations of 0.05 mg/ml antibiotic gentamycin (Sigma Aldrich, 
USA) and 0.025 HEPES buffer (Gibco, USA). Cells were routinely maintained at 37 °C in a 
5% CO2 in a humidified incubator. Cells were maintained by replacing old growth medium 
(DMEM) with equal amount of fresh growth medium after rinsing once with 5 ml PBS when 
not confluent. The culture flasks were routinely examined for changes using an inverted 
microscope and this determined the frequency of media changes. The cells were sub-cultured 
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when at near-confluency, at least once per week, and excess sub-cultures were preserved at ≥ 
-70 °C in DMEM growth medium supplemented with 20% FBS and 10% DMSO (dimethyl 
sulfoxide) (Sigma-Aldrich, USA).   
Tissue culture flasks with an estimated confluency of 70-80% were used for all the 
experiments. To harvest the cells to be used for toxicity studies, old media was discarded and 
cells were washed once with phosphate buffered saline (PBS) (Gibco, USA). Following 
washing, cells were trypsinized for 3 minutes in a humidified atmosphere incubator at 37 ⁰C 
and 5% CO2 with 2 ml of 50% trypsin solution for HEK293T and 100% trypsin solution for 
TZM-bl cells. Trypsinization was stopped by resuspending the trypsinized cells in 8 ml 
DMEM. 
Cell counting was performed by using the trypan blue exclusion technique with a ratio of 
(90:10 v/v) of trypan blue: cell suspension, respectively (Miyoshi et al., 1982). 
Hemocytometer slides were used for cells counting. Only the translucent cells under the 
inverted light microscope were counted as viable cells and dark blue stained cells were 
considered non-viable. The number of viable cells per ml was calculated using the following 
formula:  
 
     
  ⁄  
                            
 
                                              
 
Cell counting, using the above formula, is useful in calculating the number of cells to seed 
per well during an experiment.  
All cell culture procedures were carried out in a Class III biological safety cabinet. The unit 
was swabbed /sterilized with 70% ethanol before each use.  
3.7.3 Viral strains   
MJ4 
The following reagent was obtained through the NIH AIDS Reagent Program, (Division of 
AIDS, NIAID, NIH) HIV-1 MJ4 Infectious Molecular Clone (pMJ4) from Drs. Thumbi 
Ndung‟u, Boris Renjifo and Max Essex. 
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pMJ4 is an infectious HIV-1 subtype C molecular clone from a southern African (Botswana) 
isolate. For a detailed construction of this plasmid refer to Ndung‟u et al., (2001).  
CM9 
The following reagent was obtained from the NHLS (NICD). It was isolated from a 30 year 
old female in 1999 in Johannesburg, South Africa. The viral isolates were obtained by using 
PBMC co-cultured with phytohemagglutinin (PHA)-activated donor PBMC. CM9 is a 
subtype C HIV-1 that uses both CCR5 and CXCR4 chemokine receptors.  
For detailed full-length genome analysis of this HIV-1 isolate, refer to Papathanasopoulos et 
al., (2002).   
Du179 
The following reagent was obtained from the NHLS (NICD). It was obtained from an 
individual that was infected in KZN in 1998. Du179 is a subtype C HIV-1 that uses both 
CCR5 and CXCR4 chemokine receptors. 
For a detailed characterization of this isolate, refer to van Harmelen et al., (2001)  
Vesicular stomatitis virus (VSV) 
The following reagent was obtained through the NIH AIDS Reagent Program, (Division of 
AIDS, NIAID, NIH) pHEF-VSVG from Dr. Lung-Ji Chang. 
This construct is a VSV-G envelope eukaryotic expression vector. Transfection of this 
construct in mammalian cells produces a high concentration of VSV-G which can be used for 
pseudotyping retroviral- and lentiviral-based vectors.  
For a detailed construction of this plasmid refer to Chang et al., (1999).  
HIV-1 93MW965 (MW) molecular construct  
The following reagent was obtained through the NIH AIDS Reagent Program, (Division of 
AIDS, NIAID, NIH) from Dr. Paolo Miotti and the UNAIDS Network for HIV.  
The virus was isolated from seropositive individuals from the following countries: Malawi 
(MW), India (IN), Kenya (KE), Brazil (BR), South Africa (ZA), Tanzania (TZ), or China 
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(CN). Subtyping determined by sequencing a short sequence of the gag and/or env genes 
shows that this is a subtype C HIV-1 isolate that uses CCR5 chemokine receptor. 
Murine leukemia virus (MLV) molecular construct  
The following reagent was obtained through the NIH AIDS Reagent Program, (Division of 
AIDS, NIAID, NIH) SV-A-MLV-env from Dr. Nathaniel Landau and Dr. Dan Littman. 
This construct contains the amphotropic murine leukemia virus env gene linked to the MLV 
LTR, and an SV40 origin.   
For a detailed construction of this plasmid refer to Landau et al., (1991).  
We used more than one viral isolate in this study because we wanted to confirm the anti-HIV-
1 activity by the ethanol-, dereplicated ethanol- extracts and the isolated compound 2. Anti-
HIV-1 RT activity was tested against the following HIV isolates: MJ4, CM9 and Du179. 
Secondly, we wanted to evaluate if the ethanol- and dereplicated ethanol- extracts have a 
specific or non-specific neutralization activity (i.e. can the extracts specifically prevent HIV-
1 entry or can it also inhibit other viruses from infecting their host cells?). Specific 
neutralization activity was tested against the following viral strains: HIV-1 (MW), VSV and 
MLV.    
3.8 Production of HIV-1 subtype C pseudoviruses 
Production of HIV-1 subtype C pseudoviruses  
Principle of the HEK293T assay   
The assay uses human host cells to produce virus-like particles (pseudoviruses) with foreign 
viral envelope proteins that are capable of single-cycle infection.  Env-pseudoviruses are only 
capable of a single round of infection and contain a firefly luciferase reporter gene (luc); 
hence, precise quantitation of viral infection is possible 48–72 h post-infection. 
 
For transfection, 1.24 x    HEK293T cells were seeded in 10 ml supplemented DMEM in a 
culture dish 5 hours prior to addition of a transfection mixture comprising plasmid DNA, 
DMEM and polyethylenimine (PEI) (Polysciences, Inc., Warrington, PA, USA) that 
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facilitated DNA transport into the cells. The HIV-1 (HIV-1 subtype C) gag-pol construct, 
p8.9MJ4 (Naldini et al., 1996), VSV-g envelope construct, pMD.G (Naldini et al., 1996), and 
firefly luciferase reporter construct pCSFLW (Demaison et al., 2002) at a ratio of 1:1:1.5 
respectively were mixed gently with 150 µl plain DMEM and 10.5 µl of 1 mg/ml of the 
transfection reagent (PEI). The mixture was incubated at room temperature for 15 minutes 
prior to adding it dropwise to the plated HEK293T cells. Following transfection, the cells 
were incubated at 37 ⁰C, 5% CO2 for 48 hours. Virus-containing supernatants were harvested 
at 48 hours post transfection. Viral titers were determined by infecting HEK293T cells with 
serial dilutions of virus-containing supernatants. After 48 hours, the expression of firefly 
luciferase was determined with the Bright-Glo luciferase assay substrate (Promega, 
Fitchburg, WI, USA) on a Victor3 multilabel reader (PerkinElmer, Waltham, MA, USA). 
Virus inocula were standardized to produce a luminescence of                relative 
light units (RLU) after 48 hours of incubation with HEK293T cells in drug-free medium. 
Figure 3.2 below shows a diagrammatical representation for the production of pseudoviruses 
that have a luciferase reporter RNA.  
  
Figure 3.2: Diagrammatic representation of the production of HIV-1 subtype C 
pseudoviruses with luciferase reporter RNA 
Three plasmids were used to generate MJ4 HIV-1 subtype C pseudoviruses; namely, pMD.G, 
p8.MJ4 and pSCFLW. These plasmids encode genes responsible for Vesicular stomatitis 
virus glycoprotein envelope (VSV-G), HIV enzymes together with gag-polyprotein, and 
firefly luciferase RNA, respectively. Co-transfection of HEK293T cells with the three 
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plasmids was facilitated by polyethylenimine (PEI). Cells were then incubated for 48-72 
hours at 37 ⁰C, 5% CO2 in a humidified incubator. The resultant pseudoviruses, after co-
transfection, had all the required components for successful single-cycle infection: protease 
(PR), reverse transcriptase (RT), integrase (INT), capsid, luciferase RNA (Luc RNA) and 
Vesicular stomatitis virus glycoprotein envelope (VSV-G). The generation of the other HIV 
isolates (CM9 and Du179) used the same method and the only exception being the different 
HIV plasmids.  
The production of pseudovirions for the neutralization assay used the same protocol with the 
only exception being the molecular constructs (i.e. HIV-1 93MW965 (MW); VSV & MLV)   
 
3.9  Cytotoxicity assay 
Test sample preparation  
The samples to be tested for toxicity and anti-HIV activity were dissolved in 100% DMSO 
and further diluted with plain media so as to prepare working concentrations. The DMSO 
stocks for all test samples were prepared to a final concentration of 10 mg/ml and stored at -
70⁰C. Working concentrations were prepared by making a 200 µg/ml solution from a 10 
mg/ml DMSO stock solution. The 200 µg/ml was further subjected to a 3-fold serial dilution 
with complete media. The highest test sample concentration used to test for toxicity was 100 
µg/ml. The minimum concentration was 0.00169 µg/ml.  
3.9.1  CellTiter 96 Aqueous One Solution Cell Proliferation assay  
Principle of the assay  
The CellTiter 96 AQueous One Solution, (Promega, USA) was used to evaluate toxicity of 
the extracts and isolated compounds. This kit contains the tetrazolium salt, MTS [3-(4, 5-
dimethylthiazol-2-yl)-5-(3-caboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt] and an electron coupling reagent, phenazine ethosulfate. This is a colorimetric assay and 
is used to measure cellular proliferation or viability and cytotoxicity. The pale-yellow 
substrate, MTS, is converted to formazan by dehydrogenase enzymes (which cleave the 
tetrazolium ring to produce soluble formazan crystals in the presence of an electron coupling 
reagent) found in the mitochondria of viable cells. The solubilized MTS formazan can then 
be measured using a spectrophotometer at a wavelength of 490nm to quantify cellular 
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viability. Since MTS can only be reduced in metabolically active cells, it can thus be used to 
determine the number of viable cells versus non-viable cells. 
Application 
An MTS assay was conducted to measure the cytotoxicity effects of the ethanol-, dereplicated 
ethanol-, aqueous herbal concoction- extracts and isolated compounds on the cell lines 
outlined above (HEK293T and TZM-bl). Fifty microliters of cell suspension with 2     
HEK293T cells were seeded per well into 96-well microtiter plates. Cells were treated with 
50 µl of varying concentrations of the herbal extracts (100, 33.33, 11.11, 3.70, 1.23, 0.412, 
0.137, 0.0457, 0.0152, 0.00508 and 0.00169 μg/ ml, w/v) and the isolated compounds (100, 
33.33, 11.11, 3.70, 1.23, 0.412, 0.137, 0.0457, 0.0152, 0.00508 and 0.00169 μg/ ml, w/v), 
respectively, for 48 hours at 37 ⁰C, 5% CO2. The total volume per well was 100 µl. The MTS 
solution was added to each well at 20:100 µl, v/v and incubated at 37 ⁰C, 5% CO2 for 1 hour 
and the absorbance read at 490 nm on a Versa max tunable microplate reader (Separations, 
Molecular devices, USA). Each plate contained duplicates of test samples (treatment), drug 
blank, vehicle control (DMSO) and untreated control. At least two independent experiments 
were conducted on all the samples.  
Toxicity determination for TZM-bl cells was slightly different to that of HEK293T cells. The 
total number of cells (1    ) in 150 μl of cell suspension, were seeded per well. Also, 
DEAE-dextran was added to the media to enhance infection (Monteferoli et al., 2009). Forty 
microliters of 5 mg/ml DEAE-dextran was added to 10 ml cell suspension prior to seeding 
the cells. Cells were treated with 100 µl of varying concentrations of the herbal extracts (100, 
33.33, 11.11, 3.70, 1.23, 0.412, 0.137, 0.0457, 0.0152, 0.00508 and 0.00169 μg/ ml, w/v) and 
incubated for 48 hours at 37 ⁰C and 5% CO2 atmosphere. The same treatments were 
conducted for isolated compounds (100, 33.33, 11.11, 3.70, 1.23, 0.412, 0.137, 0.0457, 
0.0152, 0.00508 and 0.00169 μg/ ml, w/v) and incubated for 48 hours at 37 ⁰C and 5% CO2 
atmosphere. The total volume per well was 250 µl. Prior to adding the MTS solution, 150 µl 
of supernatant was removed from each well. MTS was then added to each well at 20:100 µl, 
v/v and incubated at 37 ⁰C, 5% CO2 for 1 hour and the absorbance read at 490 nm on a Versa 
max tunable microplate reader (Separations, Molecular devices, USA). Each plate contained 
duplicates of the test samples (treatment), drug blank, vehicle control (DMSO) and cell 
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control (untreated). Two independent experiments were conducted for all the samples.  The 
percentage cell viability was calculated by using the following formula: 
                 
                                     
                   
 
  
3.10 In Vitro Single-Cycle Non-Replicating Phenotypic Assay 
Anti-HIV activity of potential compounds is evaluated by either using enzymatic assays or 
whole-cell assays. The former assay is important in that it helps with determining the IC50 of 
the compounds tested. However, the drawback of this assay is that it lacks the ability to 
determine the toxicity of the compound(s) toward the host cells. And, conversely, whole-cell 
assays can determine both the CC50 (cytotoxic concentrations) and IC50 (inhibitory 
concentrations). Whole-cell assays are especially useful in initial high throughput screening 
of potential effective compounds. This is because they can provide a researcher with 
information regarding the toxicity of an active compound, thus early chemical modifications 
to reduce toxicity and enhance target specificity of the compound can be conducted to avoid 
unnecessary animal tests, and to reduce the number of late-stage failures in drug discovery & 
development.  
To determine the anti-HIV activity of the test samples, several concentrations were tested. 
The concentrations used were slightly cytotoxic because at the highest concentrations tested 
(100 μg/ ml), the organic extracts and compounds had IC80 values of 20-15%, as determined 
from the cytotoxicity studies. These slightly-cytotoxic concentrations were serially diluted 
using a 3-fold dilution factor.  Figure 3.3 below depicts a diagrammatical representation of a 
typical in vitro single-cycle, non-replicating phenotypic assay. Derivatives of this assay 
include RT- and PR- phenotypic assays, as shall be shown in Figures 3.4 & 3.5 below.  
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Figure 3.3: Diagrammatical representation of the HIV single-cycle non-replicative 
phenotypic assay 
Principle of the phenotypic assay 
A novel phenotypic assay to test for drug susceptibility of HIV isolate was developed by 
Gupta et al., (2010); Naldini et al., (1996) and Naldini et al., (2006). The assay is a whole-cell 
based assay that uses HEK293T cells to measure infectivity activity of HIV pseudoviral 
isolates following treatment with potential inhibitory drug candidates. The assay is a single-
round infection luciferase reporter assay that uses HIV pseudoviruses with luciferase RNA 
instead of HIV RNA. During an assay, the pseudoviruses are allowed to infect HEK239T, 
and as a result the luciferase RNA is reverse transcribed by HIV RT and integrated into the 
host genome by the HIV INT. The integrated luciferase RNA is then translated to a luciferase 
enzyme protein by host factors during the RNA translation process. The expression of 
luciferase enzyme is directly proportional to the activity of infection. During an infection, 
that is to say, when there are drug inhibitors of HIV, a maximum or higher luciferase 
expression is obtained and, hence, higher luminescence (see Figure 3.3).  
While, on the other hand, if the treatment is inhibiting any of the three HIV enzymes, the 
infectivity of those treatments will be lowered (see Figures 3.4-3.5 below). Therefore, to 
quantify the infectivity activity, a luciferase substrate is added and the conversion of this 
substrate to a colorimetric by-product is measured as a function of relative light units (RLU) 
by a luminometer.  
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3.10.1  Principle of the phenotypic reverse transcriptase (RT) assay 
This assay is directed at evaluating RT inhibitors. The principle of the assay is that inhibition 
of RT will result in no reverse transcription of the single-stranded Luc RNA and, hence, it 
will not be integrated into the host genome. This implies that no RNA translation of Luc 
RNA to protein will occur and, therefore, no luciferase enzyme to convert the substrate to a 
colorimetric by-product that can be quantified (see Figure 3.4 below).     
 
Figure 3.4: Diagrammatical representation of the phenotypic HIV-RT single-cycle, non-
replicative assay 
Application  
Three plasmids were utilized for the production of virus-like particles: pMD.G to facilitate 
viral entry, pCSFLW for the detection of viral integration by bioluminescence, and p8.MJ4 
for the expression of HIV-1 subtype C PR-RT. Plasmids were co-transfected into HEK293T 
cells in which cotransfection was facilitated with polyethylenimine as discussed above.  
 
For drug susceptibility assays, duplicate serial dilutions of all test samples (3 herbal extracts 
and the isolated compounds) and positive controls nevirapine (NVP) and zidovudine (AZT) 
(NIH AIDS Reagent Program) were prepared in 96-wells cell culture plates to which 
standardized virus inocula and 2     HEK293T cells per well were added. After incubation 
for 48 hours 37 ⁰C and 5% CO2 atmosphere, the expression of luciferase was determined 
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using a Bright-Glo luciferase substrate solution. The substrate solution was added to each 
well in the ratio 100:100µl, v/v and incubated for 2 minutes at 25 ⁰C and the contents, 
thereafter, transferred to a black 96-well plate and the luminescence (Relative Light Units: 
RLU) measured on a Victor3 multilabel reader (PerkinElmer, Waltham, MA, USA). 
 
A total of three HIV isolates (MJ4, CM9 and Du179) were used in this study. The initial 
screening used the MJ4 isolate and the test samples that showed anti-RT activity were further 
screened against the additional isolates (CM9 and Du179). Each virus was screened in at least 
two independent assays for each test sample, and the 50% inhibitory concentration (IC50) 
values were calculated.  
 
3.10.2 Principle of the phenotypic protease (PR) assay 
This assay is directed at evaluating PR inhibitors. In this assay, pseudoviruses are produced in 
the presence of PR inhibitors (PI) or test compounds and the produced pseudoviruses 
(supernatant) used to infect freshly plated cells that can express luminescence which can be 
quantified. The logic behind this approach is that if there‟s a PI during pseudovirion 
production, then the end result will be fewer/no pseudoviruses produced due the fact that no 
cleavage of gag and gag-polyprotein and viral maturation processes will occur and, hence, no 
budding of new pseudoviruses will happen. This implies that if the supernatant (supposed to 
be rich with pseudoviruses) was to be used in a new experiment to test for anti-PR activity by 
quantifying expression of luciferase (as in the RT assay), the RLU readings on the 
luminometer will be very low. Since the RLU reading is directly proportional to protease 
activity in this assay, low RLU is indicative of low virus infectivity activity. The following 
diagram (Figure 3.5) depicts the effects of inhibiting PR in this assay. 
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Figure 3.5: Diagrammatical representation of the phenotypic HIV-PR single-cycle, non-
replicative assay 
The diagram shows a series of events that occur when pseudoviruses are produced in the 
presence of an HIV protease inhibitor (PI). The gag and gag-pol polyproteins are expressed 
from the p8.MJ4 plasmid DNA (not the integrated luciferase or viral DNA). Also, the 
pseudoviruses are formed, but they are immature. Infection will occur because the 
pseudovirions will contain the VSV-g proteins on the surface. The signal RLU output will be 
lower because of the uncleaved gag, RT and INT. The PI will inhibit PR from cleaving gag 
and gag-pol polyproteins to yield immature virions. This will result in a supernatant that 
either has fewer functional pseudoviruses or none depending on the concentration of the drug 
used. The supernatant obtained from this reaction is used in the PR single-cycle, non-
replicative phenotypic assay.     
Application  
This assay has three steps which makes it slightly different to the RT assay. The first step is 
to produce pseudoviruses in the presence of the test compounds/drugs. The second step is to 
use the pseudovirus containing supernatant for treating fresh cells. The last step is to evaluate 
anti-PR activity. 
Plasmids were co-transfected into HEK293T cells, in which cotransfection was facilitated 
with polyethylenimine and incubated for 24 hours at 37⁰ C and 5% CO2 atmosphere. 
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Following transfection, the supernatant was removed and the transfected cells washed with 
PBS, trypsinized and harvested as discussed above and plated in a 96-well plate. 100 µl of 
cells were plated into wells containing duplicate serial dilutions of all test samples (3 herbal 
extracts and the isolated compounds), vehicle control, cell control (untreated) and the positive 
control Lopinavir (LPV) (NIH AIDS Reagent Program) and incubated for 24 hours at 37 ⁰C 
and 5% CO2 atmosphere.  
 
For the drug susceptibility PR assay, 25 µl of supernatant was transferred into a new 96-well 
plate in which 75 µl of fresh 2.025      HEK293T cells were seeded and incubated for 48 
hours at 37 ⁰C and 5% CO2 atmosphere. The expression of luciferase was determined using a 
Bright-Glo luciferase substrate solution. The substrate solution was added to each well at the 
ratio 100:100 µl, v/v and incubated for 2 minutes at room temperature and the contents, 
thereafter, transferred to a black 96-well plate and the luminescence (Relative Light Units: 
RLU) measured on a Victor3 multilabel reader (PerkinElmer, Waltham, MA, USA).      
The MJ4 HIV isolate was used for this assay and was screened in at least two independent 
assays for each test sample. 
3.10.3 Neutralization assay (viral entry TZM-b1 assay) 
Principle of the assay  
This is a luciferase (Luc) reporter gene assay that measures HIV neutralization as a function 
of Tat-regulated Luc reporter gene expression reduction after a single round of HIV infection 
in TZM-b1 cells (Montefiori, 2005). The assay is designed for single infection because of the 
use of Env-pseudotyped viruses generated by co-transfection of HEK293T cells with HIV-
env expressing plasmid plus an HIV backbone plasmid containing all the other HIV genes 
except the env gene.   
 
For the purpose of this study, this assay was used to evaluate HIV-1 viral entry inhibition 
following treatment of cells (TZM-b1) with test samples in the presence of the pseudoviruses 
expressing HIV-1 gp160 glycoprotein. The assay was also used to determine the CC50 and 
IC50 of the test samples. CC50 is defined as the concentration of the drug that causes 50% 
cytotoxic effect. HIV-1 93MW965 isolate was used as the pseudovirion for this assay. 
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Studies on VSV and MLV were also conducted in order to determine if the samples have a 
specific or non-specific entry inhibition mechanism.   
 
HIV entry inhibitory activity was tested by initially diluting the MW HIV pseudoviruses 3-
fold as dictated by the titration experiments to standardize virus inocula. Fifty microliters of 
standardized virus per well was incubated with the various serially diluted test sample 
concentrations for an hour prior to adding TZM-bl cells. This one hour incubation step is 
done in order to allow the test samples to interact with the virus (gp160 to be specific). 
Following the one hour incubation, 100 µl of 1     DEAE-dextran treated TZM-bl cells 
were seeded per well in a 96-well plate. The plates were incubated for 48 hours at 37 ⁰C and 
5% CO2 in a humidified atmosphere. 
 
The total volume per well was 250 µl (i.e. 100 µl drug, 50 µl virus, 100 µl cells). After the 
48-hours incubation, prior to adding the Bright-Glo luciferase assay substrate solution, 150 µl 
of supernatant was carefully removed from each well. A volume of hundred microliters of 
Bright-Glo luciferase assay substrate solution was then added to each well at the ratio 
(100:100 µl, v/v) and incubated for 2 minutes at room temperature in the dark.  Thereafter, 
the contents were transferred to a black 96-well plate and the luminescence (Relative Light 
Units: RLU) measured on a Victor3 multilabel reader (PerkinElmer, Waltham, MA, USA). 
Each plate contained duplicates of test samples (treatment), virus control (cell infected with 
virus), vehicle control (DMSO), positive control (virus treated with broadly neutralizing 
antibodies such as VRC01 (a CD4 antagonist)) and cell control (untreated & not infected 
cells). At least two independent experiments were conducted for all the samples. Percent 
activity was calculated by using the following formula:  
 
                    
                     
                           
     
     
The 50% inhibitory concentration (IC50) and 50% cytotoxic concentration (CC50) values were 
calculated and estimated by using GraphPad Prism 5
®
 (GraphPad Software, Inc. La Jolla, 
CA, USA) and Microsoft Excel (using linear forecasting algorithm to estimate a value that 
will have 50% activity).  
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3.11 Statistical analysis  
The results of each series of experiments (performed in duplicate) are expressed as the mean 
values ± standard deviation (SD) of the mean. Levels of statistical significance were 
calculated using the paired student t-test when comparing two groups or by one-way and 
factorial analysis of variance (ANOVA) for comparison of more than two groups. ANOVA 
Post Hoc analysis: Bonferroni was also conducted. P-values of ≤ 0.05 were considered 
significant. The calculations were conducted by using the GraphPad Prism 5
®
 (GraphPad 
Software, Inc. La Jolla, CA, USA) software.    
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4 CHAPTER 4 
Results and Discussion 
Brief overview of the results and discussion 
Three herbal extracts were prepared by macerating with absolute ethanol and water. A 
portion of the ethanol extract was dereplicated to make the second extract. And lastly, an 
aqueous extract was prepared according to the method used by traditional health 
practitioners. The ethanol-, dereplicated ethanol- and aqueous- extracts were prepared from a 
herbal concoction comprised of a mixture of six plants. This herbal concoction was 
investigated for anti-HIV-1 subtype C activity.  
The extracts were phytochemically characterized by thin layer chromatography (TLC) and/or 
ultra-performance liquid chromatography so as to chemically profile what type of 
compounds/phytochemicals are present in the different extracts. The ethanol- and 
dereplicated ethanol- extracts of the herbal concoction showed the presence of intermediate 
polar compounds (flavonoids, alkaloids, sugars and terpenes) while the aqueous extract had 
predominantly highly polar compounds.  
Among the three extracts, the ethanol extract and the dereplicated ethanol extract of the 
herbal concoction showed moderate anti-reverse transcriptase activity. (The ethanol extract 
had a mean fifty percent inhibitory concentration (IC50) of 56.53, 53.96 and 55.39 µg/ml 
against the MJ4, Du179 and CM9 HIV-1 isolates, respectively. The dereplicated ethanol 
extract had a mean IC50 of 51.87, 47.56 and 52.81 µg/ml against MJ4, Du179 and CM9 HIV 
1 isolates, respectively.  
Moreover, both extracts showed activity against HIV entry. These extracts were able to 
neutralize HIV-1 and, hence, reduce HIV replication and infection. The ethanol and 
dereplicated ethanol extracts had mean IC50 activities of 36.33 and 32.06 µg/ml, respectively. 
Furthermore, they also potently neutralized Vesicular stomatitis virus (VSV) yielding mean 
IC50 values of 24.91 and 20.82 µg/ml for ethanol- and dereplicated ethanol- extracts, 
respectively.  
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The isolation and phytochemical characterization of bioactive compounds using various 
chromatographic and spectroscopic methods yielded four homoisoflavones. Furthermore, the 
data also shows that the isolated homoisoflavones belong to either of the three basic structural 
types: 3-benzyl-4-chromanone (Compound 1), 3-benzylidene-4-chromanone (compound 2) 
and 3-benzyl-chrom-2-en-4-one & 3-benzylidene-4chromanone types (Compound 3, an 
isomer composed of the two types). Three of these compounds (1, 3a and 3b) were inactive 
while compound 2 was found to be bioactive against HIV-RT and yielded the mean IC50 
values of 7.228 ± 1.88, 12.83 ± 0.412 & 12.81 ± 0.1020 µg/ml against MJ4, CM9 and Du179 
HIV-1 subtype C isolates, respectively. Compound 2 induced cytotoxicity in a concentration 
dependent manner with a calculated mean CC50 value of 23.08 ± 0.1980 µg/ml against 
HEK293T cells.  
The positive controls used for anti-RT, anti-PR and HIV-1 neutralization were NVP, LPV 
and VRC01, respectively. NVP had mean IC50 values of 0.19, 0.13 and 0.12 µg/ml against 
MJ4, CM9 and Du179, respectively. LPV had an IC50 value of 5.78 µg/ml. Lastly, VRC01 
control had mean IC50 values of 0.08, 0.15 and 0.04 µg/ml against MW, VSV and MLV, 
respectively.    
These results suggest that the South African herbal extract used by herbalists possesses dual 
activity against HIV-1: the interaction of the homoisoflavones with the HIV-1 RT and/or 
blocking HIV entry into host cells during an infection. Additionally, the extract has broad 
spectrum activity, as seen from its ability to inhibit VSV and possessing homoisoflavonoid 
phytochemicals that can deal with other disorders that are linked to HIV infection such as 
oxidative stress and acute/chronic inflammatory reaction. 
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4.1 Chemical profiling of the herbal concoction and plant extracts 
Aim: To determine the metabolic profile of the herbal extracts 
Several scientific studies have found that determining the chemical profile of plant extracts 
helped in identifying some of the phytochemicals present and also provided guidance for 
further research on pharmacological activity in support of traditional uses.  
Metabolomic profiling of plant extracts using either qualitative and/or quantitative analyses 
of cellular metabolites afford a comprehensive view of the biochemical status of an organism 
(Fiehn et al., 2000; Summer et al., 2003 and Fukusaki et al., 2005). Secondary metabolites are 
generally diverse in their respective physicochemical properties (molecular weight, polarity, 
solubility, volatility). Multiple analyses are required to elucidate all of the metabolome of an 
organism. There are different metabolomic approaches that have been developed for the 
varied secondary metabolites. These include metabolite target analysis (qualitative and 
quantitative analysis of specific metabolites related to a specific metabolic reaction); 
metabolite fingerprinting (sample classification by rapid, global analysis); metabonomics 
(evaluation of tissues and biological fluids for changes in endogenous metabolite levels); and 
metabolite profiling (identification and quantification of a selected number of pre-defined 
metabolites, generally related to a specific metabolic pathway) (Duun et al., 2005; Fukusaki 
et al., 2005 and Allwood et al., 2008).   
In the present study, we have attempted to phytochemically/chemically profile the herbal 
extracts utilized for the anti-HIV-1 screening and characterization. To achieve this goal, we 
have used thin layer chromatography (TLC) and Ultra-performance liquid chromatography-
high definition mass spectrometry (UPLC-HDMS).    
4.2 Thin-layer chromatography (TLC) 
Secondary metabolite chemical profiling using TLC analysis of the ethanol extracts of the six 
individual plants together with the herbal concoction allowed partial phytochemical 
characterization of the extracts. The TLC plate image (Figure 4.1) below shows the 
separation of the extracts. TLC was used for obtaining estimate phytochemical profiles of the 
extracts and provided an indicative separation of the constituents of the samples. Terpenes 
(pink stain), flavonoids (yellow-orange stain), sugars and alkaloids (blackish-brown stain) 
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were found to be present in the ethanol extracts of W. salutaris, S. natalensis, E. autumnalis, 
S. aculeastrum, and C. miniata, respectively.  
 
Figure 4.1: UV and vanillin sprayed chemical profiles of the individual plants and the 
ethanol herbal concoction. 
The seven lanes represented above in (a), (b) and (e) (from left to right) correspond to the 
ethanol herbal-, S. aculeastrum-, S. natalensis-, E. autumnalis-, W. salutaris-, C. miniata- and 
H. surratensis- extract, respectively.  
Figure 4.1 (a) shows the UV chromatogram profile of the different extracts. The separation 
was achieved by using non-polar hexane:ethyl acetate (7:3) solvent system. Figure 4.1 (b) 
depicts the chromogenic chromatogram profile of Figure 4.1 (a) visualized by using vanillin-
H2SO4 reagent. Figure 4.1 (c) depicts the chromogenic chromatogram profiles of the ethanol 
herbal concoction separated by non-polar hexane:ethyl acetate (7:3) and polar 
chloroform:methanol (8:2)) solvent systems. Figure 4.1 (d) depicts the chromogenic 
chromatogram profile of the ethanol herbal concoction, S. aculeastrum and S. natalensis 
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visualized by using Dragendorff reagent. Figure 4.1 (e) depicts the chromogenic 
chromatogram profile of Figures 4.1 (a) and (b) but separated by using chloroform:methanol 
(8:2) polar solvent system and visualized by using vanillin-H2SO4 reagent. Figure 4.1 (f) 
depicts the chromogenic chromatogram profile of C. miniata separated by using ethyl acetate: 
methanol (5:1) and visualized by using Dragendorff reagent. Visualization was done under 
UV at 254 and 366 nm wavelengths and spraying with vanillin-H2SO4 or Dragendorff reagent 
followed by baking the TLC plate at 100 °C for 1 minute.  
Choosing a suitable solvent system to isolate compounds from plant extracts entails trying 
out several combinations of organic solvents that have different polarities. A good solvent 
system should be able to properly separate the different phytochemicals within the extract. 
We have conducted these separation studies, and found that the use of a polar system 
comprised of chloroform and methanol (8:2 v/v) can fractionate the herbal concoction Figure 
4.1 (c).  
However, the use of this solvent system for isolating compounds using column 
chromatography resulted in fractions that were not poorly resolved. The desired intermediate 
polar phytochemicals co-migrated with the solvent front and hence eluted early. Therefore, a 
different solvent system that will retard the elution of polar compounds and, hence, yield 
properly resolved fractions was investigated. We found that the use of a non-polar system 
composed of hexane: ethyl acetate (7:3 v/v) as seen in Figure 4.1 (c) would result in 
retarding the elution of polar phytochemicals. 
Figure 4.1 (c) also shows the complex phytochemical composition of the herbal concoction 
when compared with individual plant extracts as seen in Figure 4.1 (a, b and e). In general, 
Figure 4.1 c depicts a phytochemical profile of the herbal extract which shows the presence 
of different phytochemicals. It showed that terpenes (stain pink), flavonoids (yellow-orange), 
sugars and alkaloids (blackish-brown) were present in W. salutaris, S. natalensis, E. 
autumnalis, S. aculeastrum, and C. miniata, respectively.  
Ethanol extract of S. aculeastrum in Figure 4.1 (a and b) lane 2 shows that it contains 
alkaloids and sugars as major compounds but the separation was poor with this solvent 
system; hence, only a black intense spot at the baseline is observed. Conversely, Figure 4.1 
(e) lane 2 shows partial separation of the alkaloids that were retarded at the baseline in 
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Figure 4.1 (b) which is indicative that this extract contains polar compounds. The presence 
and abundance of alkaloids in this plant extract was also confirmed by the alkaloid specific 
Dragendorff spray reagent as seen from the highlighted box in Figure 4.1 (d).  
As expected, our results correlate with literature studies by Harbone et al., 1993 and 
Usubillaga et al., 1997 who have shown that the solanum species is rich in glycosidic 
steroidal alkaloids. Several pharmacological activity studies (Hostettmann et al., 1982; 
Marston et al., 1985; Young et al., 1996; Wanyoyi et al., 2002 and Laban et al., 2015) of the 
genus Solanum have shown that these types of alkaloids are responsible for most of the 
observed biological activity such as anti-molluscidal, antimicrobial activity and anti-
gonorrheal activity (Kokwaro et al., 2009).      
Ethanol extract of S. natalensis as seen in lane 3 of Figure 4.1 (a, b and e) also did not 
separate well in both polar and non-polar solvent systems. Both Figures 4.1 (a and b) show a 
similar phytochemical pattern. Furthermore, in Figure 4.1(a), faint dark spots can be seen 
which indicates that the plant has UV-active compounds and thus some level of double bond 
conjugation (indicative that metabolites such as aromatic compounds are present in this 
extract). Figure 4.1 (b), on the other hand, shows the chromogenic chromatogram of Figure 
4.1 (a), and from it, faint bands of the same compounds are seen in Figure 4.1 (a) staining 
yellow-orange. This color reaction is indicative of flavonoids, which are known to possess 
some aromatic rings. Figure 4.1 (b) corroborates what is seen in Figure 4.1 (a). A literature 
review of the phytochemicals present in S. natalensis confirms the presence of flavonoids; 
specifically, homoisoflavones and the fact that they are one of the major constituents of this 
plant species (Crouch et al., 1999; Moodley et al., 2004 and Mulholland et al., 2013).    
The ethanol extract of E. autumnalis as seen in lane 4 for both Figure 4.1 (a) and (b) was 
poorly resolved. Both Figure 4.1 (a) and (b) show a similar phytochemical pattern. The 
chromatogram of the extract of the bulbs was characterized by three main bands, which 
occurred as dark spots under UV and turned a striking orange when treated with vanillin-
H2SO4 reagent. The observed orange color is indicative of the presence of flavonoids Figure 
4.1 (b). These flavonoids are able to quench UV light and thus we observe pronounced dark 
spots in Figure 4.1 (a). This UV light quenching ability is attributed to the fact that they 
possess double bond conjugation properties (i.e. aromatics). A literature search of the 
phytochemicals present in E. autumnalis confirms the presence of flavonoids; specifically, 
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homoisoflavanoids and the fact that they are the major constituents of this plant species 
(Sidwell et al., 1970; Farkas et al., 1971; Tamm et al., 1972 and Mulholland et al., 2013).   
The ethanol extract of W. salutaris Figure 4.1 (a), (b) and (e) lane 5 depicts distinctively 
different phytochemical patterns under UV at 254 and 366 nm wavelengths and after 
spraying with vanillin-H2SO4 reagent. Figure 4.1 (a) shows that W. salutaris contains fewer 
UV-active compounds whereas Figure 4.1 (b) and (e) show an array of different compounds 
present in this extract. W. salutaris separated well with the non-polar system Figure 4.1 (b) 
compared to the polar system Figure 4.1 (e). The presence of terpenes was observed which 
typically stain pink/purple when treated with vanillin-H2SO4 reagent. Figure 4.1 (b) again 
shows that this extract possesses quite a few non-polar compounds which have migrated up 
the TLC plate. Furthermore, the presence of the major constituents of W. salutaris are also 
observed. The two circled spots in Figure 4.1 (a) and (b) lane 5, belong to the two major W. 
salutaris phytochemicals known as Warburganal and Polygodial which are both UV-active 
and chromogenic with Rf values of approximately 0.39 and 0.47, respectively.  
Our results are in agreement with the results of the studies by Drewes et al., 2001 which have 
shown that the bark of this plant contains more of Warburganal and Polygodial which have 
approximately similar Rf values, UV-activity and chromogenic activity. A literature search of 
the phytochemicals present in W. salutaris confirms the presence of terpenes; specifically, 
drimane sesquiterpenoid aldehydes, which are the major constituents of this plant species 
(Zschocke et al., 2000; Drewes et al., 2001).     
The ethanol extract of C. miniata, Figure 4.1 (a, b and e) lane 6 depicts distinctively different 
phytochemical patterns under UV at 254 and 366 nm wavelengths and after spraying with 
vanillin-H2SO4 reagent. Figure 4.1 (a) shows that C. miniata contains fewer UV-active 
compounds whereas Figure 4.1 (b and e) show an array of different compounds present in 
this extract. This also shows the importance of using various visualization techniques when 
conducting phytochemical profiling studies using TLC.  Both Figure 4.1 (a) and (b) lane 6, 
also show that the alkaloids retarded at the baseline are both UV-active and chromogenic. 
Figure 4.1 (f) shows the properly separated alkaloids that were retained at the baseline in 
Figure 4.1 (b) and visualized by Dragendorff reagent. The solvent system used in Figure 4.1 
(f) was EtOAc: MeOH (5:1) and, therefore, by comparing Figure 4.1 (a), (b), (e) and (f) it 
was concluded that this was the solvent system that would be used to isolate the alkaloids 
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present in this extract.  A literature search for the phytochemicals present in C. miniata 
confirmed the presence of alkaloids; specifically, the isoquinoline type that are the major 
constituents of this plant species These compounds are implicated in the antiviral activity 
induced by this plant species (Ieven et al., 1982; Ieven et al., 1983; Gabrielsen et al., 1992; 
Szlávik et al., 2004 and Li et al., 2005).  
The ethanol extract of H. surratensis (lane 7) in Figure 4.1 (a), (b) and (c) show that this 
extract contains very few phytochemicals. A literature search for the phytochemicals present 
in H. surratensis yielded no results. As it stands, it seems that there are no phytochemical 
studies conducted on this plant species. The observation that the ethanol extract of this plant 
contains fewer phytochemicals can be attributed to the fact that different plant parts contain 
differential amounts of phytochemicals. This differential phytochemical composition is 
dictated largely by the function these plant parts play (i.e. storage, transport and 
manufacturing of plant nutrients). As one would expect, the stems of most plants would 
contain fewer phytochemicals because they function to transport these phytochemicals back-
and-forth to-and-from the roots and leaves. Therefore, this might, in part, explain why this 
extract contains fewer phytochemicals (see Table 2 for plant parts used in extract 
preparation).  
4.3 Chemical profiling of herbal extracts by UPLC-HDMS 
Particular base peak intensities (BPI) chromatograms have been included here and show the 
chemical profiles of some of the extracts obtained from the different solvents.  
For the purpose of comparison of the chemical profiles from the various extracts, attention 
will be placed on the ESI- and ESI+ BPI chromatograms (depending on which show better 
ionization of the compounds). The ESI- chromatograms of the ethanolic herbal extract, 
dereplicated ethanolic herbal extract and aqueous herbal extract are discussed below.  
To corroborate the above observations, and phytochemically profile these extracts, Ultra 
performance liquid chromatography coupled to high definition mass spectrometry (UPLC-
HDMS) was used for the analyses. This is because UPLC-HDMS can yield properly resolved 
base peak intensities (BPI) peaks corresponding to individual compounds present within the 
extract. UPLC-HDMS allows qualitative analysis of the BPI peaks and, thus, it is possible to 
VN Hlatshwayo: MSc Dissertation  
 
79 
 
determine more accurately the elemental composition of the isolated molecules, accurate 
molecular weight, identification and structure elucidation of the separated compounds.  
Figures 4.2 a, b and c shows visual examination of the BPI chromatograms at the negative 
electro spray ionization (ESI
-
) mode of the different herbal extracts. The chromatograms 
indicate clearly that the ethanol- and dereplicated ethanol- extracts have different 
phytochemicals when compared to the aqueous extract. Therefore, as expected, we can see 
that the different solvents used for extraction induced differential secondary metabolite 
changes. This is demonstrated by the increase and decreases of molecular ion peak 
intensities, the appearance of new molecular ion peaks and suppression of some molecular 
ion peaks which are present in other BPI chromatograms of the extracts. 
VN Hlatshwayo: MSc Dissertation  
 
80 
 
 
 
Figure 4.2: The BPI chemical profile chromatogram of the dereplicated ethanol extract of the herbal concoction in ESI- mode. 
The profile shows the retention times and molecular masses of the various compounds present in the extract. The polarity range of the 
column is depicted by the red boxes (i.e. from left to right; polar region, intermediate polar region and nonpolar region). The y-axis shows 
the percentage intensity and the x-axis shows the time gradient used in running the UPLC separation.   
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Figure 4.3: The BPI chemical profile chromatogram of the ethanol extract of the herbal concoction in ESI- mode. 
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Figure 4.4: The BPI chemical profile chromatogram of the aqueous extract of the herbal concoction in ESI- mode. 
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Upon visual inspection of the BPI chromatograms of the three herbal extracts, it is evident 
that the organic solvent (ethanol) extracted secondary metabolites ranging from non-polar to 
mid-polar whereas those extracted by water (aqueous extract) are polar. The dereplicated 
ethanol extract profile (Figure 4.2) shows that there is not much difference observed when 
compared to the BPI chemical profile chromatogram of the ethanol extract profile (Figure 
4.3). And, with regard to the polarity classes, both extracts (Figures 4.2 and 4.3) have similar 
compounds. Visual examination of these two BPI chemical profiles shows that the only 
difference is the reduced molecular ion peak intensity of the intermediate polar compounds 
for the dereplicated ethanol extract. This suggests that the dereplication of the ethanol extract 
has resulted in removal of some of the intermediate polyphenols.  
The ethanol extract BPI chemical profile (Figure 4.3) shows that it is composed of various 
phytochemical classes, including fewer polar- metabolites (eluting at 1-6 mins), high 
intensity intermediately polar metabolites (6-12 mins) and few nonpolar metabolites (13-20 
mins). The ethanol extract is, therefore, composed mostly, of intermediate polar metabolites 
when compared to dereplicated ethanol extract as shown by pronounced peak intensities 
(Figure 4.3) versus (Figure 4.2). 
The aqueous extract profile (Figure 4.4) as expected, revealed that the extract contains 
mostly polar metabolites when compared to ethanol extracts (Figures 4.2 and 4.3) which 
showed the dominance of intermediate region. 
Furthermore, examining both the TLC and UPLC-HDMS data, the ethanol extract would be 
an ideal extract to use for the isolation of bioactive compounds as it contains appreciable 
variation of metabolites. 
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Possible implications of these results in relation to the bioactivity of these 
extracts 
Based on the results obtained for the chemical profiling of the herbal extracts, there are 
several possible outcomes to expect in the screening of these extracts for anti-HIV activity. 
The following hypotheses are proposed:  
1. The ethanol extract will induce moderate anti-HIV activity. 
 
This is substantiated by the fact that this extract has various phytochemicals present and, thus, 
an increased probability of having phytochemicals that have antagonistic activity to the 
bioactive compounds present in this extract.  
2. The dereplicated ethanol extract will induce increased activity when compared to the 
ethanol extract. 
3. The dereplicated ethanol extract will induce slightly increased cytotoxic activity 
when compared to the ethanol extract. 
The removal of antagonistic polyphenolic phytochemicals will result in enhanced cytotoxic 
activity. The fact that this extract contains fewer polar phytochemicals means that the more 
abundant intermediate polar compounds will not have bioavailibity issues (i.e. they can cross 
the cellular membrane and, thus, be able to reach intracellular targets such as RT and PR). 
With regard to toxicity, the extract will cause slightly higher cytotoxic activity because 
“beneficial” polyphenols that were antagonizing to the cytotoxic compounds may have been 
non-selectively dereplicated together with the tannins. 
4 The aqueous extract will be inactive. 
5 The aqueous extract will be non-cytotoxic. 
 
This extract will be inactive because there are fewer intermediate polar compounds and more 
polar compounds extracted. This presents challenges with the bioavailability of the 
compounds. Polar compounds have challenges with passing though the lipid bilayer and, 
therefore, they will not reach intracellular targets such RT and PR in a whole-cell assay 
system such as those used in this study. The extract will be non-cytotoxic because polar 
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compounds will not be able to interact with intracellular proteins such as Cytochrome P450 
(CYT P450 that are implicated in triggering toxicity effects.  
4.4 Bioactivity of the herbal extracts 
Aim: This study section is aimed at evaluating the anti-HIV-1 activity of the herbal 
extracts  
The objectives followed to realise the aim: 
 Determine the cytotoxicity of the extracts 
 Evaluate if the extracts have anti-reverse transcriptase activity   
 Evaluate if the extracts have anti-protease activity  
 Evaluate if the extracts can neutralize HIV and, therefore, inhibit HIV entry  
4.5 Cytotoxicity studies   
The antiviral activity of plant extracts against HIV infection is occasionally a result of their 
toxic effects and subsequently might result in inaccurate conclusions. Therefore, to exclude 
the non-specific antiviral effect, the toxicity of plant extracts on HEK293T and TZM-bl cells 
was assessed using the TMS assay as outlined in the methods and materials (section 3.9.1). 
The CC50 values of the herbal extracts were obtained and are summarized in Table 5 below. 
Briefly, the ethanol-, dereplicated ethanol- and aqueous- herbal concoction extracts yielded 
approximately 42, 4.0 and 51% cell viability respectively at 100 µg/ml when compared with 
the untreated cell control of HEK293T cells. The ethanol- and dereplicated ethanol- herbal 
extracts were cytotoxic to HEK293T and TZM-bl cells in a dose-dependent manner. Both of 
the positive controls (AZT and NVP) were not cytotoxic at the maximum and minimum 
concentrations tested 100-0.0017 µg/ml, respectively (data not shown). The vehicle control 
(DMSO) did not affect the cell viability at all concentrations including those evaluated for 
anti-reverse transcriptase activity (see Figures below). In this study CC50 values for plant 
herbal extracts   40 µg/ml were considered toxic and CC50   100 µg/ml were considered 
non-toxic. 
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4.6 Anti-reverse transcriptase activity studies 
Given that HIV-1 is a retrovirus, reverse transcriptase (RT) is one of the important virally 
encoded enzymes that catalyzes the conversion of viral RNA to proviral DNA, thus, 
presenting an important target for discovering antiretroviral therapeutics. Consequently, the 
RT activity was evaluated in the presence and absence of extracts using a novel phenotypic 
drug susceptibility assay as outlined in the methods and materials (section 3.10.1). The IC50 
values of the herbal extracts and the positive controls that were obtained are summarized in 
Tables 5 and 6. Briefly, the ethanol-, dereplicated ethanol- and aqueous- herbal extracts at 
100 µg/ml yielded approximately 18, 1.0 and 72% of RT activity, respectively when 
compared with the untreated cell control. 
Graphical representation of the cytotoxicity results by all the herbal extracts evaluated in this 
study, DMSO and anti-reverse transcriptase by the extracts and the positive controls for all 
the HIV isolates are shown in Figures 4.5 to Figure 4.7. 
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Table 5: In vitro cytotoxicity and anti-HIV activity of the herbal extracts using 
HEK293T and TZM-bl cells 
Plant extracts  Viral strain  *CC50 
(µg/ml) 
*IC50 (µg/ml) *SI 
HEK293T Cells 
Ethanol extract      MJ4 92.95      56.53 1.644 
     Du179      53.96 1.723 
     CM9      55.39 1.671 
Dereplicated 
ethanol extract 
     MJ4 66.17      51.87 1.276 
     Du179      47.56 1.391 
     CM9      52.81 1.253 
Aqueous extract      MJ4 100.9      Inactive - 
     Du179      Inactive - 
     CM9      Inactive - 
TZM-bl cells 
Ethanol extract     MW 72.51      36.33 1.996 
    VSV      24.91 2.912 
    MLV      52.87 1.372 
Dereplicated 
ethanol extract 
    MW 61.98      32.06 1.933 
    VSV      20.82 2.978 
    MLV      43.12 1.437 
Aqueous extract     MW 193.0      Inactive - 
    VSV      Inactive - 
    MLV      Inactive - 
*CC50 (the concentration required to kill 50% of the cells) was estimated by using Graph Pad Prism 
5
®
 and Microsoft Excel (using linear forecasting algorithm to estimate a value that will have 50% 
activity).  
*IC50 (the concentration required to inhibit 50% of the reverse transcriptase activity) was estimated by 
using Graph Pad Prism 5
®
 and Microsoft Excel (using a linear forecasting algorithm to estimate a 
value that will have 50% activity).   
*SI is the ratio of cytotoxicity to inhibitory activity = CC50/IC50 
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Table 6: Cytotoxicity and inhibitory activity of positive controls 
Positive controls  Viral strain *CC50 (µg/ml) 
*
IC50 (µg/ml) 
HEK293T Cells 
NVP MJ4 >100 0.189 
 Du179  0.130 
 CM9  0.119 
AZT MJ4 >100 0.0826 
 Du179  0.0535 
 CM9  0.0182 
LPV MJ4 >100 5.775 
TZM-bl cells 
VRC01 MW n/a 0.0815 
 VSV n/a 0.153 
 MLV n/a 0.0390 
*CC50 (the concentration required to kill 50% of the cells) was estimated by using Graph Pad Prism 
5
®
 and Microsoft Excel (using linear forecasting algorithm to estimate a value that will have 50% 
activity).  
*IC50 (the concentration required to inhibit 50% of the reverse transcriptase activity) was estimated by 
using Graph Pad Prism 5
®
 and Microsoft Excel (using a linear forecasting algorithm to estimate a 
value that will have 50% activity). 
n/a: not available (VRC01 is a potent CD4 binding site broadly neutralizing antibody, therefore it is 
not toxic).  
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4.7 Cytotoxicity and anti-reverse transcriptase (RT) activity of the ethanol extract 
In this study, general extraction procedures and plant extract preparations were followed, 
some of which mimic the traditional preparations (see section 3.2) and others more 
scientifically accepted extraction procedures (i.e. using organic solvents for extraction). 
These were done for standardization purpose and comparison of the activities present in the 
different preparations (see section 3.2 and 3.4).  
The ability of the ethanol herbal extract to inhibit HIV-1 RT was investigated using a novel 
RT phenotypic drug susceptibility assay. Cells were infected with either of the three HIV-1 
isolates, namely, MJ4, Du179 and CM9. Following infection, cells were then treated with the 
ethanol extract at various concentrations followed by a 48 hour incubation. Culture 
supernatant was collected after 48 hours for Luciferase expression estimation by 
luminescence. AZT and NVP were included as positive controls and the results expressed as 
percent virus activity relative to control (100%). Cytotoxicity due to vehicle control (DMSO) 
was also evaluated and results expressed as percentage viability relative to control. Data 
points are representative of mean percent activity   SD of two independent experiments: 
n=4; p< 0.05 was considered significant. Figures 4.5 to 4.7 below show the graphical 
representation of the findings from these studies. 
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Figure 4.5: Reverse transcriptase phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to the ethanol extract 
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Figure 4.6: Reverse transcriptase phenotypic drug susceptibility profile of Du179 HIV-1 subtype C isolate to the ethanol extract. 
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Figure 4.7: Reverse transcriptase phenotypic drug susceptibility profile of CM9 HIV-1 subtype C isolate to the ethanol extract. 
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4.8 Cytotoxicity and anti-reverse transcriptase (RT) activity of the dereplicated 
ethanol extract  
As indicated earlier (section 3.4.3), studies by Cardellina et al., (1993) indicated that tannins 
present in plant extracts are responsible for the false positive results observed especially in 
studies of HIV and medicinal plants. Therefore, in the present study, we attempted to remove 
tannins from the ethanol herbal extract with the aim of determining whether they were 
responsible for the observed anti-HIV-1 activity or whether other compounds within the 
extract were responsible for the observed activity. Tannins were removed as outlined in the 
Methods and Materials section and this extract (“dereplicated ethanol extract”) subjected to 
the same anti-HIV investigations as the ethanol herbal extract. Below (Figures 4.8 to 4.10) 
are the findings of both cytotoxicity and anti-RT activity by this extract. 
Phenotypic drug susceptibility of the MJ4 HIV-1 subtype C isolate to the dereplicated ethanol 
extract was assessed using a novel RT phenotypic drug susceptibility assay. Cells were 
infected with either three of the HIV-1 isolates, namely, MJ4, Du179 and CM9. Infected cells 
were then treated with the dereplicated extract at various concentrations followed by a 48 
hour incubation. Culture supernatant was collected after 48 hours for Luciferase expression 
estimation by luminescence. Results are expressed as percentage of activity relative to control 
(100%). The toxicity to HEK293T cells was also investigated. AZT and NVP were included 
as positive controls and their results expressed as percent virus activity relative to control 
(100%). Cytotoxicity due to vehicle control (DMSO) was also evaluated and results 
expressed as percentage viability relative to control. Data points are representative of mean 
percent activity   SD of two independent experiments: n=4; p< 0.05 was considered 
significant.
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Figure 4.8: Reverse transcriptase phenotypic drug susceptibility profile of a MJ4 HIV-1 subtype C isolate to dereplicated ethanol 
extract. 
VN Hlatshwayo: MSc Dissertation  
 
95 
 
 
Figure 4.9: Reverse transcriptase phenotypic drug susceptibility profile of a Du179 HIV-1 subtype C isolate to dereplicated ethanol 
extract. 
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Figure 4.10: Reverse transcriptase phenotypic drug susceptibility profile of a CM9 HIV-1 subtype C isolate to dereplicated ethanol 
extract.  
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4.9 Cytotoxicity and in vitro phenotypic reverse transcriptase (RT) activity of the 
aqueous herbal concoction 
In this section, the traditional healer‟s extraction technique was mimicked as outlined in the 
Methods and Materials section. This yielded an aqueous extract which was used to evaluate 
its ability to inhibit HIV infection. Figure 4.11 below depicts the findings of this extract 
treatment with regard to cytotoxicity and anti-RT activity.  
Phenotypic drug susceptibility of the MJ4 HIV-1 subtype C isolate to aqueous herbal extract 
was assessed using a novel RT phenotypic drug susceptibility assay. Cells were infected with 
an HIV-1 MJ4 isolate and treated with extracts at various concentrations followed by a 48 
hour incubation. Culture supernatant was collected after 48 hours for Luciferase expression 
estimation by luminescence. Results are expressed as percentage of activity relative to control 
(100%). The toxicity to HEK293T cells was also investigated. AZT and NVP were included 
as positive controls and their results expressed as percent virus activity relative to control 
(100%). Cytotoxicity due to vehicle control (DMSO) was also evaluated and results 
expressed as percentage viability relative to control. Data points are representative of mean 
percent activity   SD of two independent experiments: n=4; p< 0.05 was considered 
significant. 
The extract was not active and, thus, we only screened for anti-RT activity against the MJ4 
HIV-1 subtype C isolate and not the other isolates (i.e. Du179 and CM9). This was also done 
for all inactive extracts not only for anti-RT but for other assays as well.  
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Figure 4.11: Reverse transcriptase phenotypic drug susceptibility profile of a MJ4 HIV-1 subtype C isolate to aqueous extract. 
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4.10 Description and discussion of the anti-RT activity by the herbal extracts 
Figures. 4.5-4.7 show the toxicity of the ethanol herbal extract to HEK293T cells (“toxicity” 
curve). The extract yielded a mean CC50 value of 92.95  23.32 µg/ml. Furthermore, the 
dereplicated ethanol herbal extract yielded a mean CC50 value of 66.17  2.300 µg/ml and 
both extracts induced cytotoxicity to HEK293T cells in a concentration dependent manner 
and found to be non-toxic at concentrations below 100 µg/ml.  
Comparison of the ethanol extract and the dereplicated ethanol extract showed that the 
removal of tannins enhanced the cytotoxicity of the dereplicated extract. This data suggests 
that during the dereplication process, phytochemicals that had a protective effect were also 
removed, thus, enhancing cytotoxicity. Also, the dereplication process improved the 
inhibitory activity of the dereplicated extract slightly as seen from the slight change of the 
IC50 values, before and after tannin removal. This is also indicative of the removal of 
phytochemicals that had antagonistic activity to the active phytochemicals. The aqueous 
extract on the one hand yielded a mean CC50 value of 100.9  8.969 µg/ml and was found to 
be non-toxic to HEK293T cells at all concentration ranges.  
Vehicle control (DMSO) did not affect the cell growth and, therefore, the observed 
cytotoxicity and anti-RT activity is a result of treatment with the ethanol-, dereplicated 
ethanol- and aqueous- extracts. The positive controls (AZT & NVP) behaved as expected for 
the anti-RT assay and, thus, it was concluded that the assay was valid and proceeded with 
data analysis.  
The shifting of anti-RT activity curves (“MJ4-, Du179- and CM9- Act”) to the left and 
downwards of the “toxicity” curve is indicative of inhibitory activity, while a shift to the right 
and upwards indicates no inhibitory activity. From the plots above (Figures 4.5-4.10), it is 
evident that all three viruses behave the same with regard to drug susceptibility following 
treatment with ethanol- and dereplicated ethanol- extracts at various concentrations.  
Table 5 has a summary of the mean IC50 values of all viral isolates (MJ4, CM9 and Du179) 
for all the treatments investigated. From this table, the IC50 values lie within the 50-55 µg/ml 
range, which indicative of a moderate inhibitory activity exerted by the two extracts (ethanol- 
and dereplicated ethanol- extracts). Potent inhibitory activity by extracts lies below the 50-55 
µg/ml range (IC50 50 µg/ml) while inactivity is expected to be IC50   100 µg/ml. Therefore, 
VN Hlatshwayo: MSc Dissertation  
 
100 
 
in this study, it was shown that the aqueous herbal extract has an IC50 value above 100 µg/ml 
and, hence, this extract was considered to be inactive against HIV-1 RT.   
Figures 4.5-4.10 furthermore, show that from concentration 33.33 µg/ml, the activity of 
HIV-1 RT starts to decline and eventually it is completely inhibited at 100 µg/ml by the 
dereplicated ethanol extract and partially inhibited by the ethanol extract. It should be noted 
that the observed, complete and partial inhibitory activity at 100 µg/ml is attributed to 
cytotoxicity rather than true HIV-1 RT inhibition. At 33.33 µg/ml, toxicity is calculated as 
1.000% and anti-HIV-1 RT activity as 33.00, 33.00 and 36.00% against MJ4, CM9 and 
Du179 respectively, for the ethanol extract. While, on the other hand, the dereplicated ethanol 
extract at the same concentration showed anti-HIV-1 RT activity to be 31.00, 30.00 and 
36.00% for MJ4, CM9 and Du179, respectively.    
Overall, these results suggest that both the ethanol- and dereplicated ethanol- herbal extracts 
have moderate activity against HIV-1 RT at 33.33 µg/ml. Tan et al (1991) have found that 
crude plant extracts that yield IC50 values in the range of 10-50 µg/ml usually have a single or 
fewer RT inhibitors in low concentration in the extract. We, therefore, assume that these 
extracts have fewer phytochemicals that can inhibit HIV-RT.  
Statistical analysis, using factorial ANOVA followed by Bonferroni post hoc analysis, 
indicated that the viral isolate (MJ4, Du179 and CM9) and the relationship between dosage 
and virus subtype do not have a significant effect (p>0.05) to the observed anti-HIV-1 RT 
activity. However, both Two-way and factorial ANOVA followed by Bonferroni post hoc 
analysis indicated that dosage alone (i.e. concentration treatment of 33.33 µg/ml) is 
accountable for the observed significant difference (p<0.001) between toxicity and anti-RT 
activity induced by these two ethanol extracts.   
A possible explanation for the observed anti-HIV-1 RT activity of the ethanol extracts is that 
these extracts encompass a plethora of phytochemicals such as terpenes, flavonoids, alkaloids 
and polysaccharides as depicted and discussed in section 4.1, Figure 4.1 (c). Moreover, 
chemical analysis of these ethanol extracts as depicted in section 4.3, Figures 4.2 and 4.3, 
implies that intermediate polar compounds are responsible for the observed anti-RT activity.  
Other studies by Bedoya et al., (2001); Rukunga et al., (2002); Bessong et al., (2004); 
Bessong et al., (2005); and Bessong et al., (2006), have also reported that organic extracts 
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from medicinal plants are more inhibitory than the aqueous extracts in screening for anti-HIV 
activity. This is because organic solvents such as ethanol, methanol, chloroform etc. extract a 
range of phytochemicals that are relatively less polar when compared to the water-extracted 
phytochemicals. Additionally, studies by Hughes et al., (2008) showed that there is a link 
between toxicity, activity and the physiochemical properties of drugs/phytochemicals. The 
authors found that more polar drugs in whole-cell systems have a decreased activity and 
toxicity when compared with more non-polar drugs. Furthermore, they showed that drugs 
with intermediate polarity have moderate activity with occasional toxicity.  
This trend was indeed observed in this study. As previously stated, our findings from section 
4.3 (Figures 4.2 and 4.3) showed that the ethanol extracts are mostly composed of 
intermediate polar phytochemicals. Biological screening (Figures 4.5-4.10) of these extracts 
showed that they possess moderate activity and therefore they may contain single/fewer RT 
inhibitors, and also, they are non-cytotoxic at various concentrations excluding 100µg/ml. 
Contrary to the above findings, the aqueous extract was found to be inactive and non-
cytotoxic at all concentrations. There are several possible explanations for the observed 
findings of the treatment with the aqueous extract. Firstly, this might be due to the fact that 
the preparation of aqueous extract mimicking the traditional healer resulted in degrading 
thermoliable phytochemicals that may be potentially bioactive.  
Secondly, the aqueous extract is mostly comprised of polar phytochemicals rather than 
intermediate polar compounds (Figure 4.4). This presents issues with the bioavailability of 
the compounds within the extract. This, is because polar compounds have been shown to 
have higher log P values which is related to poor absorption of these compounds through 
biological membranes and, hence, their distribution in tissues and intracellular targets such 
HIV-1 RT and PR in a whole-cell assay system is decreased (Edward et al., 2003).  
The fact that this extract is non-cytotoxic is ascribed to it having more polar phytochemicals 
and, thus, their inability to interact with intracellular proteins such as the 10 nuclear receptors 
(androgen, estrogen a, estrogen b, glucocorticoid, liver X, mineralocorticoid, peroxisome 
proliferator-activated receptor g, progesterone, thyroid a, thyroid b), four members of the 
cytochrome P450 enzyme family (1A2, 2C9, 2D6, 3A4), a cytosolic transcription factor (aryl 
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hydrocarbon receptor) and a potassium ion channel (hERG) which are implicated in 
triggering toxicity effects (Vedani et al., 2015).  
Statistical analysis revealed that there is no significant difference (p>0.05) between 
cytotoxicity and anti-RT activity for the aqueous extract which indicates that this extract is 
inactive at all the concentrations tested for anti-RT activity.  
To predict the relative safety profiles of these extracts for consumption by patients, we 
calculated the selective index (SI). This is the ratio between the toxic and the therapeutic dose 
and is used as a measure of its relative safety. “Safe to consume” drugs/therapeutic products 
by patients have minimum SI values > 5 to start of with. The SI values of the ethanol- and 
dereplicated ethanol- extracts are in the range of 1-2 which is below the minimum SI values 
for “Safe to consume” drugs/therapeutic products. Therefore, an SI value < 5 indicates that 
the extract/drug should be taken with care and in lower quantities to avoid severe side effects 
and drug poisoning.  
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4.11 Cytotoxicity and in vitro phenotypic protease (PR) activity of the ethanol extract 
of the herbal concoction 
HIV-1 protease is one of the most important enzymes in the HIV life cycle. It functions at 
post-entry level. Protease is responsible for facilitating the assembly and association of the 
viral components at the host cell membrane which then buds off as immature virions. 
Protease activity continues after budding from the host cell to ensure maturation into a fully 
infectious virion. Because of this, it is also an ideal target as an antiretroviral therapeutic. We 
have also screened our extracts against HIV-1 subtype C protease using a novel protease 
phenotypic drug susceptibility whole-cell assay system and the results are shown in Figure 
4.12 to Figure 4.14. 
The extracts (ethanol-, dereplicated ethanol- and aqueous- herbal extracts) were evaluated for 
anti-HIV-1 PR activity utilizing a novel protease phenotypic drug susceptibility assay. Cells 
were infected with an HIV-1 MJ4 isolate and treated with extracts at various concentrations 
followed by a 48 hours incubation. Culture supernatant was collected after 48 hours for 
Luciferase expression estimation by luminescence. Results are expressed as percentage of 
activity relative to control (100%). The toxicity to HEK293T cells was also investigated. 
Lopinavir (LPV) was included as a positive control and DMSO as a vehicle control with 
results expressed as percentage activity and viability relative to control. Data points are 
representative of mean percent activity   SD of two independent experiments: n=4; p< 0.05 
was considered significant. 
Upon inspection and analysis of the data obtained for the anti-PR activity by all three 
extracts, it is evident that all three extracts do not possess anti-PR activity. No left and 
downward shift was observed for all extracts. Extract treatment resulted in no difference 
between activity and toxicity. The activity plots (Figures 4.12-4.14) overlap with toxicity 
plots.  
In all experiments, the vehicle control (DMSO) did not affect the cell growth and, hence, the 
observed cytotoxicity and anti-PR activity is a result of the ethanol, dereplicated ethanol and 
aqueous extract treatments. The positive control Lopinavir (LPV) behaved as expected for 
anti-PR assay and, thus, it was concluded that the assay was valid and proceeded with data 
analysis.  
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Statistical analysis using a student t-test also confirmed these findings. There was no 
significant difference between activity (treated samples) and untreated samples. Calculated p-
values greater than 0.05 (p>0.05) at all the concentrations screened were obtained.
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Figure 4.12: Protease phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to the ethanol extract. 
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Figure 4.13: Protease phenotypic drug susceptibility profile of a MJ4 HIV-1 subtype C isolate to the dereplicated ethanol extract. 
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Figure 4.14: Protease phenotypic drug susceptibility profile of a MJ4 HIV-1 subtype C isolate to the aqueous extract.  
VN Hlatshwayo: MSc Dissertation  
 
108 
 
4.12 Neutralization activity (viral entry TZM-b1 assay) 
Given that the ethanolic extracts showed anti-HIV activities against different HIV strains, 
their anti-HIV mechanisms were explored further. The HIV entry process, is made up of three 
stages: gp120-CD4 electrostatic interaction, gp120-CCR5/CXCR4 chemokine interaction and 
membrane fusion. These are regarded as attractive targets for chemotherapeutic intervention, 
because blocking HIV entry into its target cell leads to suppression of viral infectivity, 
replication and the production of progeny virions.  
The possibility of the ethanolic extracts to inhibit HIV-1 subtype C entry into target host cells 
was also investigated in this study. The entry inhibition specificity of the extracts (i.e. 
whether the extracts are only HIV-1 specific in their inhibition or not) was evaluated and, 
hence, two other non-HIV viruses namely, Vesicular stomatitis virus (VSV) and Murine 
leukemia virus (MLV) were used. To accomplish this, the neutralization TZM-bl assay was 
used.  
The results obtained for anti-HIV infection suggest that the ethanol extract and the 
dereplicated ethanol extract have activity whereas the aqueous herbal extract does not. Both 
empirical and visual evaluation and analysis of the data and the plots, confirm that these two 
extracts have anti-HIV entry activity as seen by the downward and left shifting of the curves 
in Figure 4.15 and Figure 4.18. 
However, these extracts were not HIV specific in their entry inhibitory activity since there 
was activity also obtained against VSV (Figure 4.16 and Figure 4.19). The inhibitory 
activity against VSV was more potent when compared to that of HIV at 33.33 µg/ml. 
Furthermore, cytotoxicity against VSV was lower and slightly higher for MW HIV-1 isolate 
when treated with ethanol- and dereplicated ethanol- extracts respectively. The extracts were 
cytotoxic against MLV (Figures 4.17 and 4.20) and this was confirmed by statistical analysis 
which showed that there is no significant difference between toxicity and activity at all 
concentrations. The aqueous extract was also found to be inactive against the MW HIV-1 
isolate following empirical and statistical analysis at all concentrations tested. Figures 4.15-
4.21 below depicts graphically the above stated observations. VRC01 (a CD4 antagonist) and 
DMSO were included as positive and vehicle controls respectively. Data points are 
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representative of mean percent activity   SD of two independent experiments: n=4 and p< 
0.05was considered significant.       
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Figure 4.15: HIV-1 (MW isolate) neutralization profile by the ethanol extract. 
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Figure 4.16: VSV neutralization profile by the ethanol extract. 
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Figure 4.17: MLV neutralization profile by the ethanol extract.  
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Figure 4.18: HIV-1 (MW isolate) neutralization profile by the dereplicated ethanol extract. 
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Figure 4.19: VSV neutralization profile by the dereplicated ethanol extract. 
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Figure 4.20: MLV neutralization profile by the dereplicated ethanol herbal extract. 
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Figure 4.21: HIV-1 (MW isolate) neutralization profile by the aqueous herbal extract. 
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4.13 Description and discussion of the anti-HIV-1 infection (HIV-1 entry inhibition) 
The ability of the extract to neutralize an HIV-1 MW isolate was evaluated utilizing the 
TZM-bl assay. The ethanol extract yielded a mean IC50 of 36.33   1.101 µg/ml and inhibited 
HIV-1 entry at 33.33 µg/ml (blue curve, Figure 4.15 a). Furthermore, the neutralization of 
VSV by the extract was also evaluated and yielded a mean IC50 of 24.91   1.350 µg/ml and 
significantly inhibited VSV entry at 11.11 and 33.33 µg/ml (green curve, Figure 4.16 a), p> 
0.01. The neutralization of MLV by the ethanol extract yielded a mean IC50 of 52.87 
  0.3121 µg/ml (red curve, Figure 4.17 a). The ethanol extract was non-cytotoxic (CC50 = 
72.51  23.32 µg/ml).  
The ability of the dereplicated ethanol extract to neutralize HIV-1 MW isolate was evaluated 
and yielded a mean      of 32.06   1.342 µg/ml. The extract significantly inhibited HIV-1 
MW entry at 33.33 µg/ml (Figure 4.18 a), p<0.05. Moreover, the extract was able to 
neutralize VSV and it showed a mean      of 20.82   2.251 µg/ml. The extract significantly 
inhibited HIV-1 entry at 11.11 and 33.33 µg/ml (brown curve, Figure 4.19 a), p<0.01. The 
extract further showed some activity against MLV with a mean IC50 value of 43.12   2.201 
µg/ml (brown curve, Figure 4.20 a). The extract yielded a CC50 value of 61.963  0.000 
µg/ml against TZM-b1 cells.  
The aqueous extract was inactive against MW HIV-1 isolate (brown curve, Figure 4.21 a) 
and non-cytotoxic (CC50: 192.9  2.202 µg/ml) to TZM-b1 cells. VRC01 (a CD4 antagonist, 
Figure 4.21 b) was included as a positive control and DMSO as a vehicle control (Figure 
4.21 c) in all experiments, with results expressed as percentage activity and percentage 
viability relative to control. Data points in all experiments are presentative of mean percent 
activity   SD of two independent experiments: n=4, and p< 0.05 was considered significant. 
Statistical analysis of the data for the ethanol extract at 33.33 µg/ml using students-t test and 
Two-way ANOVA followed by Bonferroni post hoc correction has shown that there is a 
significant difference (p<0.05) between anti-HIV entry and toxicity. Also, for the 
dereplicated ethanol extract there was a significant difference (p< 0.01). At this particular 
concentration (33.33 µ g/ml), the ethanol- and dereplicated ethanol extracts inhibited viral 
entry by 48.00 and 53.12% while cytotoxicity was computed to be 9.101 and 13.42%, 
respectively.  
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However, these extracts were not HIV specific in their entry inhibitory activity since there 
was activity also obtained against VSV (Figure 4.16 and Figure 4.19). The inhibitory 
activity against VSV was more potent (71.6%) when compared to that of HIV (63.9%) at 
33.33 µg/ml. Furthermore, cytotoxicity against VSV was 9.1 and against HIV 13.4% for 
ethanol and the dereplicated ethanol extracts, respectively. The extracts also had some 
activity against MLV but that was actually due to cytotoxicity and this was further confirmed 
by statistical analysis which showed that there is no significant difference between the 
toxicity and activity at all concentrations.   
These results suggest that the ethanolic extracts have phytochemicals that possess anti-HIV 
entry activity and also that these compounds have potent activity against VSV. The exact 
mode of action by these extracts is not yet known since specific tests for either of the three 
possibilities i.e. gp120-CD4, gp120-CCR5/CXCR4 interactions or fusion between the virus 
and the target host cell were not conducted. 
However, HIV neutralization by the extracts were tested. Other studies have also shown that 
medicinal plants possess anti-HIV entry activity (Rege et al., 2010; Modi et al., 2013). These 
studies have attributed the anti-HIV entry activity by most medicinal plants to be due to the 
presence of flavonoids, alkaloids and glycosides. This is indeed what has been shown above 
and this explains the observed activity by these herbal extracts which were shown to possess 
mostly flavonoids, alkaloids and glycoside “sugars” (see section 4.1 and 4.2, Figure 4.1). 
These extracts also contain antiviral alkaloids from Clivia miniata (Ieven et al., 1982) and 
hence these might be the key active principles.      
Generally, based on the findings obtained in this study, we conclude that the South African 
herbal concoction does indeed possess anti-HIV 1 activity. This anti-HIV activity is mediated 
by inhibition of the enzyme reverse transcriptase and also neutralization of HIV. However, 
the exact bioactive compounds responsible for the observed activity have not yet been 
identified and isolated.  
Therefore, in the following section (Chapter 5), the isolation and characterization of the 
potentially bioactive phytochemicals was done.  
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5 CHAPTER 5 
5.1  Isolation of the major compounds from the ethanol extract of the herbal 
concoction 
Plants provide people with primary metabolites such as carbohydrates, proteins, fats and 
vitamins. Furthermore, it has been proposed that plants produce secondary metabolites 
(alkaloids, phenols, terpenes etc.) which are essential for both humans and plants because 
they form a chemical defense mechanism in response to infection by microorganisms, 
predation, insects and herbivores. Furthermore, they also play a crucial role in aiding the 
plant to survive and adapt to environmental changes (Pengelly, 2004). Secondary metabolites 
were considered to be useless by-products of the synthesis of primary metabolites. However, 
through the science of Pharmacognosy („„the study of the physical, chemical, biochemical 
and biological properties of drugs, drug substances, or potential drugs or drug substances of 
natural origin as well as the search for new drugs from natural sources‟‟) and Ethnobotany 
(“the study of the relationship between humans and plants in all its complexity”) it was 
observed that these products are the basis of the healing properties of medicinal plants. 
Neuwinger, (1994) found that constituents with special properties often occur in a high 
concentration and sometimes with great purity in a particular medicinal plant. 
 
In this chapter, we explore further the observed anti-HIV activity of the ethanol extract by 
conducting studies to identify the active constituents. These studies included compound 
isolation, structure elucidation, characterization and biological testing. These studies were 
done in order to investigate the molecular mechanism of action of the inactive and active 
phytochemicals.   
 
This study is, to the best of our knowledge, the first reported phytochemical and biological 
study of the ethanol extract of the herbal concoction. In an effort to identify potential anti-
HIV compounds from the ethanol herbal extract, several chromatographic methods (see 
section 3.4) were used to fractionate the extracts and major compounds were isolated. The 
isolated compounds were further purified and subjected to NMR spectroscopic experiments. 
The phytochemical investigation of this extract led to the isolation of several compounds. 
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However, this section will only report on four compounds (i.e. four homoisoflavones). These 
were chosen for further studies based on their physiochemical properties (i.e. the “minor” 
differences within the same phytochemical class). Furthermore, these different compounds 
were chosen in order to show how the stereochemistry and molecular substitutions influence 
the bioactivity of phytochemicals belonging to the same class. And, again, we also wanted to 
identify which type of phytochemical category would yield a better bioactive pharmacophore 
scaffold to be further investigated in drug discovery and drug design research. The structures 
of these compounds were partially elucidated based on their 1D-NMR: 
1
H, 
13
C and MS 
spectral data.  
The flow diagram, Figure 5.1 below, shows the steps followed in the isolation of the 
homoisoflavone phytochemicals.   
 
Figure 5.1: Schematic representation of the isolation process of flavonoid compounds from the 
ethanol extract of the herbal concoction.  
Compounds F1P2, 3EA1, 3EB1.2, 3EB3 and M1 were isolated from the hexane: ethyl acetate 
fraction of the ethanol extract of the herbal concoction. Compounds 3EB1.2 and M1, upon 
analysis of their proton and carbon NMR spectra, were found to be exactly the same as 
compounds 3EA1 and F1P2, respectively. 
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5.2 Compound characterization and structure elucidation  
5.2.1 Characterization of compound 1 (3EA1) 
The 
1
H-NMR spectrum (Figure 5.3) revealed the presence of two singlets resonating at    
3.709 and 3.766 ppm integrating for three protons each, indicative of two methoxy groups. 
Five aromatic protons are observed at the region between    5.8-7.5 ppm, a sharp singlet 
resonated at    5.921 ppm and the other 4 peaks resonated at the    6.87 and 7.204 ppm 
region. Deuterated acetone solvent peaks are seen at 2.033 and 2.048 ppm.  
The
 13
C-NMR spectrum (Figure 5.4) showed compound 1 as having 18 carbons in its 
structure. A carbonyl carbon signal with a chemical shift    196.34 ppm was also observed. 
The 
13
C spectrum also revealed the presence of methoxy carbons at    54.564 and 60.037 
ppm. The aromatic ring signature signals are also observed between    113.879-158.514 
ppm. The deuterated acetone solvent peaks are observed at 28.510 and 205, 265 ppm. Both 
spectra are in complete agreement with each other, the 
13
C-NMR spectrum confirms what is 
seen in the 
1
H-NMR spectrum of this compound. These chemical shift signals are indicative 
of flavonoids specifically the 3-benzyl-4-chromanone Homoisoflavone subclass (Mulholland 
et al., 2013).  
The UPLC-MS chromatogram of the pure isolated compound 1 (Figure 5.5) showed a signal 
peak in the intermediate polarity region with a calculated mass of m/z: 329.1006 in the ESI- 
mode and a mass of m/z: 331.1262 in the ESI+ mode which then correlates with an actual 
mass of m/z: 330.0967 for this compound. This molecular mass was further confirmed by 
High Resolution Quadrupole Time Of-Flight-Mass Spectrometry (HR-QTOF-MS) (Figure 
5.6) which also yielded the same value. 
HR-QTOF-MS analysis also predicted the molecular formula of the compound to be 
C18H17O6 with a double bond equivalent (DBE) of 10 which suggests that the compound 
could have two aromatic rings and two double bonds or one double bond plus a ring. 
Considering all of the above data, we propose the backbone chemical structure for compound 
1 to be that of a 3-benzyl-4-chromanone homoisoflavone derivative as shown in Figure 5.2 
below. 
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Figure 5.2: The chemical backbone structure of compound 1, a 3-benzyl-4-chromanone 
homoisoflavone derivative.  
The “R” indicates the presence of a substituent. In order to get to the m/z: 330.0967 molecular 
mass (18 carbons, 17 hydrogens and 6 oxygens), we need the following substituents as seen 
from the proton-, carbon NMR and QTOF-MS prediction: H; 2 x OH; 2 x OCH3. The 
proposed structure above complies with the predicted DBE of 10.  
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Figure 5.3: 
1
H-NMR spectrum of compound 1 (3EA1) isolated from the ethanol extract of the herbal concoction. 
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Figure 5.4: 
13
C-NMR spectrum of compound 1 (3EA1) isolated from the ethanol extract of the herbal concoction.  
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Figure 5.5: UPLC-MS (ES- and ES+) chromatograms for compound 1. 
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Figure 5.6: HR-QTOF-MS (ES- and ES+) for compound 1. 
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5.2.1.1 Bioactivity of 3EA1 (compound 1) 
Our results suggest that compound 1 is non-cytotoxic at concentrations below 11.11 µg/ml 
against HEK293T cells. It exhibited a mean CC50 value of 14.31 ± 7.16 µg/ml against the 
HEK293T cells (Figure 5.7).  
This compound was found to be inactive against HIV-1 subtype C RT (Figure 5.7) when 
compared to the cytotoxicity plot, (no downward and left shift of the “3EA1 act” plot).  
Compound 1 was also inactive against PR compared with the cytotoxicity plot (no downward 
and left shift of the “3EA1 act” plot as seen in Figure 5.8.   
Furthermore, compound 1 was also non-toxic to TZM-bl cells with a mean CC50 value of 
88.39 ± 13.17 µg/ml and was inactive at neutralizing the HIV-1 MW isolate.  
Statistical analysis of this data also confirmed that this compound is indeed inactive against 
HIV-1. No significant difference between toxicity and activity (RT, PR and Neutralization) 
was observed following a student t-test, a Two-way ANOVA and a Bonferroni post hoc 
analysis. The p-value was found to be greater than 0.05 at all concentrations tested. 
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5.2.1.2 Cytotoxicity and RT activity 
 
Figure 5.7: Reverse transcriptase phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to compound 1. 
The ability of compound 1 to inhibit HIV RT was investigated using a novel RT phenotypic drug susceptibility assay. Cells were infected 
with a HIV-1 MJ4 isolate and treated with compound 1 at various concentrations for 48 hours. Data points are representative of mean 
percent activity ± SD of two independent experiments: n=4; p< 0.05 was considered significant. Plots of Zidovudine (“AZT”) and 
Nevirapine (“NVP”) represent positive controls and plot of “DMSO” represents the vehicle control.    
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5.2.1.3 Cytotoxicity and PR activity 
 
Figure 5.8: Protease phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to compound 1. 
Compound 1 was evaluated for anti-HIV protease activity utilizing a novel protease phenotypic drug susceptibility assay. Cells were 
infected with HIV-1 MJ4 isolate and treated with compound 1 at various concentrations for 48 hours. Data points are presentative of mean 
percent activity   SD of two independent experiments: n=4; p< 0.05 was considered significant. Plots of “LPV” represent positive control 
and plot of “DMSO” represents the vehicle control. 
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5.2.1.4 Cytotoxicity and Neutralization activity 
 
Figure 5.9: HIV-1 (MW isolate) neutralization profile for compound 1. 
The ability of this compound to neutralize a HIV-1 MW isolate was evaluated utilizing the TZM-bl assay. The extract yielded a mean CC50 
of 88.39 ± 13.17 µg/ml. Data points are representative of mean percent activity ± SD of two independent experiments: n=4; p< 0.05 was 
considered significant. Plots of “activity” represent positive control and plot of “DMSO” represent the vehicle control.
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5.2.2 CHARACTERIZATION OF COMPOUND 2 (3EB3) 
Upon viewing the 
1
H-NMR spectrum (Figure 5.11) of this compound, some interesting 
signals were observed. The spectrum revealed the presence of one singlet resonance 
integrating to three protons at    3.86 ppm which correlates to a methoxy group. Two sharp 
singlet aromatic proton signals are seen at the    5.813 and 5.866 ppm. The spectrum also 
showed the presence of two doublet signals in the 7.047-7.396 ppm region which suggest that 
compound 2 is para substituted. There appears to be an ethylene signal at    7.679 ppm. The 
deuterated acetone signal is seen at 2.033-2.077 ppm  
The 
13
Carbon-NMR spectrum (Figure 5.12) showed compound 2 having 17 carbons in its 
structure. A carbonyl carbon signal at    183.679 ppm was also observed. The 
13
C spectrum 
also revealed the presence of a methoxy carbon at    54.863 ppm. The aromatic ring 
signature signals are also observed at    114.231 and 133.203 ppm. An ethylene carbon was 
also observed at    135.089 ppm. Both spectra are in complete agreement with each other. 
13
C confirms what is seen in the 
1
H-NMR spectrum of this compound. These chemical shift 
signals are indicative of flavonoids, especially the homoisoflavones subclass, and specifically 
belonging to the 3-bezylidene-4-chromanone category of homoisoflavones (Mulholland et al., 
2013).   
The UPLC-MS chromatogram of the pure isolated compound 2 (Figure 5.13) showed a 
signal peak in the intermediate polarity region and a retention time of 10.87 minutes with a 
calculated mass of m/z: 297.0710 in the ESI- mode and a mass of m/z: 299.0911 in the ESI+ 
mode. These mass values correlate with an actual mass of m/z: 298.0732 for this compound. 
This molecular mass was further confirmed by HR-QTOF-MS (Figure 5.14) which also 
yielded the same value. Q-TOF/MS analysis also predicted the molecular formula of the 
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compound to be C17H14O5 with a double bond equivalent (DBE) of 11 which suggests that 
the compound could have two aromatic rings and three double bonds or two double bonds 
plus a ring. Taking all of the above data into consideration, we propose the backbone 
chemical structure for compound 2 to be that of an (E)-3-benzylidene-4-chromanone 
homoisoflavone as shown below. 
 
O
R1
R2
R3
R4 O
R5
 
Figure 5.10: Chemical backbone structure of compound 3a: a (E)-3-benzylidene-4-
chromanone homoisoflavone derivative.     
In order to get to the m/z: 298.0732 molecular mass, 17 carbons, 14 hydrogens and 5 
oxygens, we need the following substituents as seen from the proton-, carbon NMR and Q-
TOF-MS prediction: OH; OH; OCH3; H. The proposed structure above complies with the 
predicted DBE of 11.   
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Figure 5.11: 
1
H-NMR spectrum of compound 2 (3EB3) isolated from the ethanol extract of the herbal concoction.  
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Figure 5.12: 
13
C-NMR spectrum of compound 2 (3EB3) isolated from the ethanol extract of the herbal concoction. 
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Figure 5.13: UPLC-MS (ES- and ES+) chromatograms for compound 2. 
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Figure 5.14: HR-QTOF-MS (ES- and ES+) for compound 2.  
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5.2.2.1 Bioactivity of 3EB3 (compound 2) 
Figure 5.15 presents evidence that compound 2 was active against HIV-RT and Table 7 
depicts the mean IC50 and CC50 values of this compound. Based on the obtained IC50 and 
CC50 values, the selectivity index (SI) was calculated and found to be 3.19, 1.78 and 1.80 for 
MJ4, CM9 and Du179, respectively. These SI values are an indication that compound 2 
would have to be administered with caution if it was to be used as a therapeutic agent.  
To evaluate if indeed there is a significant difference between the means of anti-HIV-1 RT 
activity and cytotoxicity, statistical analysis of this data was conducted. Statistical tests 
included a two-way ANOVA and a Bonferroni post hoc test. The findings of these analyses 
confirmed that there is a statistically significant difference between cytotoxicity and anti-HIV 
RT activity at particular treatments.  
There was no significant difference between the mean toxicity, the anti-PR activity and the 
neutralization activity after treatment of the MJ4 isolate with compound 2 (see Figures 5.16 
and 5.17). The student t-test, Two-way ANOVA and the Bonferroni post hoc analysis have 
also confirmed these observations. The p-value was found to be greater than 0.05 at all 
concentrations tested. Figures 5.15 to 5.17 show the graphical representation of these 
findings.  
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5.2.2.2 Cytotoxicity and RT activity 
 
Figure 5.15: Reverse transcriptase phenotypic drug susceptibility profile of all three HIV-1 subtype C isolates to compound 2. 
The ability of compound 2 to inhibit HIV-1 RT was investigated by a novel drug susceptibility phenotypic assay. Zidovudine (AZT) and 
Nevirapine (NVP) were used as positive controls and their results expressed as percent virus activity relative to control. Cytotoxicity due to 
vehicle control (DMSO) was also evaluated and the results expressed as percentage viability relative to control. Data points are presentative 
of mean percent activity   SD of two independent experiments: n=4; p< 0.05 was considered significant.  
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5.2.2.3 Cytotoxicity and PR activity 
 
Figure 5.16:Protease phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to compound 2. 
To evaluate if compound 2 has anti-HIV protease activity, a protease phenotypic drug susceptibility assay was conducted. Both compounds 
were inactive against HIV-1 protease. Lopinavir (LPV) was included as a positive control and DMSO as a vehicle control with results 
expressed as percentage activity and viability relative to control. Data points are presentative of mean percent activity   SD of two 
independent experiments: n=4; p< 0.05 was considered significant.  
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5.2.2.4 Cytotoxicity and Neutralization activity 
 
Figure 5.17: HIV-1 neutralization profile for compound 2. 
The TZM-bl assay was used to evaluate the ability of the isolated compounds to neutralize HIV-1 MW isolate. Compound 2 was inactive 
for preventing HIV entry. VRC01 (CD4 antagonist) was included as a positive control and cytotoxicity due to “DMSO tox” vehicle control 
was also evaluated with results expressed as percentage activity and percentage viability relative to control. Data points are presentative of 
mean percent activity   SD of two independent experiments: n=4; p< 0.05 was considered significant.
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Table 7: Cytotoxicity and anti-RT activity of compound 2 against three HIV-1 subtype 
C isolates (MJ4, CM9 and Du179) 
Cpd IC50 (µg/ml) CC50 (µg/ml) 
Viral isolates Cell-lines 
 MJ4 CM9 Du179 HEK293T TZM-bl 
2 7.23  1.88 12.83  0.41 12.81  0.1021 23.08  0.1981 23.072  1.825 
Cpd= compound   
Bonferroni post hoc test revealed that the significant difference between anti-RT of the MJ4 
HIV isolate and toxicity was observed between the concentration ranges of 1.23 (p<0.001), 
3.70 (p<0.001) and 11.11 µg/ml (p<0.001). The difference for the CM9 HIV isolate was 
observed at 3.70 (p<0.001) and 11.11 µg/ml (p<0.001). Lastly, for the Du179 HIV isolate, 
the difference was seen from 1.23 (p<0.01), 3.70 (p<0.001) and 11.11 µg/ml (p<0.001). 
Table 8 depicts the evaluation of the mean toxicity and anti-RT activities at the above-
mentioned concentrations. 
Table 8: The mean toxicity and anti-RT activity values of the concentrations that are 
statistically significant for all three HIV viral isolates when treated with compound 2 
Dosage 
(µg/ml) 
Viral isolates 
 MJ4 CM9 Du179 
 *Act (%) 
§
Tox (%) Act (%) Tox (%) Act (%) Tox (%) 
11.11 51.3 1.2 12   3.8 45.9 3.5 12   3.8 46.0 1.9 12   3.8 
3.70 39.75 1.56 9.6  6.3 32.6 1.39 9.6 6.3 33.8 0.78 9.6 6.3 
1.23 27.6  9.40 9.1  3.9 Ns Ns 24.4 1.47 9.1 3.9 
*Act = percent activity; §= percent toxicity; ns= not significant   
Furthermore, Bonferroni post hoc test has revealed that there is a significant difference 
between the mean activity within the viral isolates. The difference is seen between MJ4 and 
CM9 at 1.23 µg/ml (p<0.05) and also between MJ4 and Du179 at 0.412 µg/ml (p<0.05). 
There was no difference was observed between CM9 and Du179 HIV isolates (p>0.05).     
The implications of the above statistical analysis are that, compound 2 is active against HIV-
1 RT and it seems to be more selective, on average, for the MJ4 HIV-1 RT isolate when 
compared to the CM9 and Du179 isolates (see Figure 5.15).   
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5.2.3 CHARACTERIZATION OF COMPOUND 3a AND 3b (F1P2) 
The 
1
H NMR spectrum of compound 3 showed that this compound was in fact composed of 
two compounds with a slight difference in the chemical structure i.e. regioisomers (see 
Figure 5.20). From this point forth, these isomers shall be referred to as compounds 3a and 
3b. The 
1H NMR spectrum shows a few interesting proton chemical shift signals (δH). The 
presence of two singlets with an integration of three protons at δH 3.87 and 3.83 ppm, indicate 
that compounds 3a and 3b have a methoxy functional group. And, the fact that two peaks for 
this functional group are observed, further correlate with the assumption that this compound 
was isolated as an isomer. Methylene signals (CH2) were also observed at δH 3.708 and 5.36 
ppm corresponding to H-9 and H-2 of compound 3b and 3a, respectively. A methyl signal 
was also observed at δH 2.07 ppm which suggests that these compounds have a methyl group 
as one of their functional groups. Furthermore, the spectrum showed a singlet at δH 5.89 ppm 
which is indicative of a substitution at the “A” ring of homoisoflavones. The spectrum also 
showed the presence of two sets of doublet signals in the δH 6.9-7.9 ppm region which 
suggest that compounds 3a and 3b are para substituted. Two sets of singlet ethylene signals at 
   6.99 and 7.71 ppm were observed which belong to H-9 and H-2 of compound 3b and 3a. 
The presence of these pairs of ethylene signals and other pairs of signals further confirm that 
compound 3 was indeed isolated as a regioisomer-type of a compound.   
The 
13
Carbon-NMR spectrum (Figure 5.21) showed compound 3 to have 18 carbons in its 
structure. However, visual inspection of Figure 5.21 showed more than 18 carbon signals, 
which is due to varied chemical shifts of the regioisomers. The 
13
C-NMR spectrum also 
revealed the presence of two methoxy carbons at    60.04 and 60.099 ppm. The aromatic 
ring signature signals are also observed in the    97.39 to 134.77 ppm range. Two ethylene 
carbons were also observed at    139.13 and 160.15 ppm corresponding to C-9 and C-2 of 
compounds 3a and 3b. Carbonyl carbon signals at    184.71 and 186.71 ppm were also 
observed. Both spectra are in complete agreement with each other (i.e. the 
13
C-NMR 
confirms what is seen in the 
1
H-NMR spectrum of this compound). These chemical shift 
signals are indicative of flavonoids; especially, the homoisoflavones subclass and specifically 
belonging to the 3-bezylidene-4-chromanone (3a) and 3-benzyl-chrom-2-en-4-one (3b) 
categories of homoisoflavones (Mulholland et al., 2013)    
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The UPLC-MS chromatogram of the pure isolated compound 3 (Figure 5.22) showed two 
signal peaks with retention times of 10.54, 10.78, 10.53 and 10.74 minutes in the intermediate 
polarity region and both peaks have equal mass in both ESI- and ESI+ modes. This further 
confirms the assumption that this compound is a regioisomer. The peaks have a calculated 
mass of m/z: 327.0815 in the ESI- mode and a calculated mass of m/z: 329.1046 in the ESI+ 
mode which then correlates with an actual mass of m/z: 328.0931 g/mol for this compound. 
This molecular mass was further confirmed by Q-TOF-MS (Figure 5.23) which also yielded 
the same value. Q-TOF-MS analysis also predicted the molecular formula of the compound 
to be C18H16O6 with a double bond equivalent (DBE) of 11 which suggests that the 
compound could have two aromatic rings and three double bonds or two double bonds and a 
ring. Based on the data provided above, we propose the backbone chemical structure for 
compound 3a to be that of the (E)-3-benzylidene-4-chromanone type and for compound 3b 
to be that of the 3-benzyl-chrom-2-en-4-one homoisoflavone type as shown below. 
O
O
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R3
R4
R5
R6
R1
 
Figure 5.18: Chemical backbone structure of compound 3a, a (E)-3-benzylidene-4-
chromanone homoisoflavone derivative. 
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Figure 5.19:Chemical backbone structure of compound 3b, a 3-benzyl-chrom-2-en-4-
one homoisoflavone derivative. 
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The proposed structures are in agreement with the predictions. However, the exact spatial 
positioning of the functional groups could not be extrapolated and, therefore, other techniques 
such as 2D NMR spectroscopy which exploit the short- and long-range correlations of the 
protons to carbons within a molecule need to be further conducted. the latter techniques will 
aid in determining the exact positions of these functional groups. Determining the exact 
position of these substituents is imperative because it will allow us to understand the 
structure-activity relationship between the ligand (compound) and its protein target (enzyme, 
receptor etc.). Therefore, this will assist further investigations into understanding the 
molecular mechanism of action of these compounds (i.e. answering questions such as: what is 
the mode of binding of the compound at the active site? Which functional groups are needed 
to elicit a biological response? and at which carbon position should they be substituted in 
order to elicit biological activity?).  
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Figure 5.20: 
1
H-NMR spectrum of compound 3 (F1P2) isolated from the ethanol extract of the herbal concoction. 
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Figure 5.21: 
13
C-NMR spectrum of compound 3 (F1P2) isolated from the ethanol extract of the herbal concoction. 
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Figure 5.22: UPLC-MS (ES- and ES+) chromatograms for compounds 3a and 3b. 
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Figure 5.23: HR-QTOF-MS (ES- and ES+) for compounds 3a and 3b. 
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5.2.3.1 Bioactivity of compound 3 (F1P2) 
As shown in Figures 5.24-5.26, the data suggests that compound 3 exerted its cytotoxic 
effect in a concentration dependent manner against HEK293T cells. Compound 3 exhibited a 
mean CC50 value of 19.32 ± 1.004 µg/ml against HEK293T cells.  
Compound 3 was found to be inactive against HIV-1 subtype C RT and PR. Furthermore, it 
was also non-toxic to TZM-bl cells with a mean CC50 value of 20.933 ± 2.375 µg/ml. 
Compound 3 was inactive in neutralizing HIV-1 subtype C.  
Statistical analysis of this data using the student-t test and Two-way ANOVA followed by the 
Bonferroni post hoc test, also confirms that there is no significant difference between anti-
HIV-1 RT, PR, neutralization activity and cellular toxicity following treatment with this 
compound at all various concentrations tested starting from 100 to 0.00169 µg/ml. Therefore, 
this implies that compound 3 was inactive against HIV-1. The p-value was found to be 
greater than 0.05 at all concentrations tested. 
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5.2.3.2 Cytotoxicity and RT activity 
 
Figure 5.24:Reverse transcriptase phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to compound 3 
The ability of compound 3 to inhibit HIV-1 RT was investigated using a novel RT phenotypic drug susceptibility assay. Cells were infected 
with HIV-1 MJ4 isolate and treated with compound 3 at various concentrations for 48 hours. Data points are presentative of mean percent 
activity   SD of two independent experiments Plots Zidovudine (“AZT”) and Nevirapine (“NVP”) represent positive controls and a plot of 
“DMSO” represents the vehicle control. n=4; p< 0.05 was considered significant. 
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5.2.3.3 Cytotoxicity and PR activity 
 
Figure 5.25: Protease phenotypic drug susceptibility profile of MJ4 HIV-1 subtype C isolate to compound 3 
Compound 3 was evaluated for anti-HIV protease activity utilizing a novel protease phenotypic drug susceptibility assay. Cells were 
infected with HIV-1 MJ4 isolate and treated with compound 3 at various concentrations for 48 hours. Data points are representative of 
mean percent activity   SD of two independent experiments. Plots of “LPV” represent positive control and plot of “DMSO” represents the 
vehicle control. n=4; p< 0.05 was considered significant. 
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5.2.3.4 Cytotoxicity and Neutralization activity 
 
Figure 5.26: HIV-1 neutralization profile of compound 3 
TZM-bl assay was used to evaluate the ability of the isolated compounds to neutralize HIV-1 MW isolate. Compound 3 was inactive for 
preventing HIV entry. VRC01 (CD4 antagonist) was included as a positive control and cytotoxicity due to DMSO vehicle control was also 
evaluated with results expressed as percentage activity and percentage viability relative to control. Data points are representative of mean 
percent activity   SD of two independent experiments: n=4; p< 0.05 was considered significant.
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6 DISCUSSION  
The results presented here show that we have managed to isolate flavonoids specifically 
belonging to the homoisoflavones class. Homoisoflavonoids belong to a small group of 
naturally occurring oxygen heterocycles (Bohler et al., 1976). Structurally, these types of 
compounds are classified as derivatives of the 4-chromanone pharmacophore (Farkas et al., 
1971 and Perjesi at al., 2008). Homoisoflavanones are characterized by a sixteen-carbon 
skeleton which has either a chromanone, chromone or chromane moiety attached to a benzyl 
or benzylidene group at the C-3 position (Namikoshni et al., 1987). There are three basic 
structural types of homoisoflavanones; namely, 3-benzyl-4-chromanone, 3-benzyl-3-
hydroxy-4-chromanone and 3-benzylidene-4-chromanone. The latter structural type can 
undergo isomerization of the exocyclic double bond to form an endocyclic double bond 
between C2 and C3 thus forming a chromone derivative (Namikoshni et al., 1987).  
The first homoisoflavanones to be isolated were eucomin and eucomol (Dewick et al., 1975). 
Subsequently, several compounds have been isolated from different genera within the 
Hyacinthaceae family including Eucomis, Merwilla, Ledebouria, Veltheimia and Drimiopsis 
(Mulholland et al., 2013). This particular 4-chromanone scaffold (Homoisoflavonoid) is one 
of the most important pharmacophores in medicinal chemistry and biologically too, it has 
been shown to possess several pharmacological activities including anti-cancer (Wall et al., 
1989; Miadokova et al., 2002 and Perjesi et al., 2008), antifungal (Nakib et al., 1990), anti-
monoamine oxidase (Desideri et al., 2011), antioxidant (Siddaiah et al., 2006 and Siddaiah et 
al., 2007), antiviral (Desideri et al., 1997; Quglia et al., 1999 and Tait et al., 2006), anti-
inflammatory (Du Toit et al., 2010 and Hung et al., 2010), antihistaminic and antiallergic 
(Kirkiacharian et al., 1989), antitubercular (Yempala et al., 2012 and Roy et al., 2013) and 
anti-protein kinase C activity (Lin et al., 2008).  
Two of the most important pharmacological activities that these compounds possess 
especially in relation to HIV/AIDS, are anti-inflammatory and antioxidant activities. Both of 
these pharmacological activities have been implicated in decelerating the progress of HIV 
infection to AIDS in HIV-positive patients (Cos et al., 2004 and Singh et al., 2005). 
Oxidative stress, which is a result of an imbalance between natural antioxidants and reactive 
oxygen species production, causes a broad range of activities including altering viral 
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replication, immune functions and apoptosis (Singh et al., 2005). Singh and colleagues have 
shown that in an HIV positive patient, the natural antioxidant response (i.e. glutathione, 
ascorbic acid and other natural antioxidants) is lowered, thus, resulting in an accumulation of 
ROS and oxidative DNA damage which, in turn, results in accelerated progression to the 
AIDS state in these patients.  
With regard to anti-inflammatory activity, it is well documented that during an infection, the 
early events of an immune response include inflammation. This is a process whereby the 
white blood cells are activated to express interleukins which, in a feedback loop mechanism, 
will also activate white blood cell expression and production of other chemical factors that 
will activate and recruit cells like macrophages, thus ensuring that the pathogenic microbes 
do not spread to the rest of the body. However, the HIV virus relies on this mechanism (since 
it infects white blood cells) to ensure its replication (Boinon et al., 2005; Paiardini and 
Muller-Trutwin, 2013). 
Therefore, a treatment that not only focuses on treating HIV alone but also considers these 
two factors is ideal. This would ensure the down-modulation of pro-inflammatory cytokines 
and, therefore, a reduced inflammation process. Furthermore, fewer white blood cells will be 
infected. Moreover, the reduction of ROS accumulation will ensure that oxidative DNA 
damage is prevented and fewer immune cells will undergo apoptosis, therefore, ensuring 
decelerated progression to the AIDS state.  
In this study, a series of compounds including alkaloids and flavonoids have been isolated. 
However, we report on only four flavonoids which were partially characterized. As seen in 
section 5.2.1-5.2.3, the data shows that these flavonoids specifically belong to the 
homoisoflavones class and are of three basic structural types. Compound 1 belongs to the 3-
benzyl-4-chromanone type, while compound 2 belongs to the 3-benzylidene-4-chromanone 
type. Compound 3 is an isomer composed of the 3-benzylidene-4-chromanone type and the 3-
benzylidene-4-chromanone type that has undergone isomerization of the exocyclic double 
bond to an endocyclic double bond forming a chromanone type of homoisoflavonone. These 
compounds have been tested for anti-HIV-1 subtype C activity.  
These different structural types have been shown to possess different bioactivities. Studies by 
Tait et al., (2006) investigating the antiviral activities of substituted homoisoflavonoids on 
VN Hlatshwayo: MSc Dissertation  
 
155 
 
enteroviruses have shown that, generally, the 3-benzylidene-4-chromanone type has a 
pronounced potent activity and they are slightly toxic when compared to the 3-benzyl-4-
chromanone type. The latter compound class has been shown to be inactive and non-toxic. 
They further showed that the chomanone type “3-benzyl-chrom-2-en-4-one” has moderate 
activity and toxicity. A structure-activity relationship evaluation of the substituted 
homoisoflavonoids showed that the presence of a methoxy group at C-5 and C-7 resulted in 
loss of activity and greater cytotoxicity against HeLa and BGM cells by the 3-benzyl-4-
chromanone types. Whereas the presence of a methoxy at C-4' of the 3-benzylidene-4-
chromanone type resulted in pronounced antiviral activity.   
Moreover, Roy et al. (2013) found that of all the homoisoflavonoid analogues they tested for 
antitubercular activity, only the 3-benzylidene-4-chromanone type was potent at inhibiting 
the efflux pump of mycobacterium smegmatis which makes it resistant to most of 
antitubercular medicines. The authors further showed that the positioning of the substituents 
on the homoisoflavonoid structural backbone and the type of substituents can alter the 
mycobacterial activity drastically.   
A study by Desideri and colleagues (2011), which looked at a different angle from 
antimicrobial to anti-neurodegeneration activity of homoisoflavonoids, showed that all three 
homoisoflavonoid structural types were active at inhibiting the two monoamine oxidase 
isoforms (MAO-A and MAO-B) but they showed selective inhibitory activity against the 
MAO-B isoform. Additionally, the 3-benzylidene-4-chromanone type was more potent even 
at nanomolar concentrations while the 3-benzyl-4-chromanone type was active only at 
micromolar concentrations. They also showed that the presence of an endocyclic double 
bond, as seen in the 3-benzyl-chrom-2-en-4-one types, resulted in a significant reduction of 
inhibitory activity and loss of activity of some analogues depending on the substitution 
pattern and the type of functional groups present in those analogues.  
Corresponding to what the above studies have found, we also observed the same trend in our 
investigation of the anti-HIV activity of homoisoflavonoids. Looking at Figures 5.7-5.9 for 
compound 1, we see that the 3-benzyl-4-chromanone types are less toxic against HEK293T 
and TZM-bI cells and inactive against HIV-1 subtype C. Moreover, it was observed that 
compound 2, the 3-benzylidene-4-chromanone type, is active against the RT of three HIV-1 
isolates (MJ4, CM9 and Du179), while inactive against HIV PR, HIV neutralization and 
VN Hlatshwayo: MSc Dissertation  
 
156 
 
moderately cytotoxic to HEK293T and TZM-bI cells (see Figures 5.15-5.17). Lastly, 
compound 3, a mixture of the chomanone “3-benzyl-chrom-2-en-4-one” and the 3-
benzylidene-4-chromanone type, was found to be inactive against HIV RT, PR and 
neutralization and moderately cytotoxic to HEK293T cells (see Figures 5.24-5.26). Figure 6 
below shows the proposed chemical structures of the isolated compounds.  
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Figure 6.1: Backbone structures of the proposed compounds 1, 2, 3a and 3b 
When comparing compound 1 and compound 2 structurally, we propose that the loss of 
activity for compound 1 could be a result of the physiochemical properties of this compound 
such as the flexibility of compound 1 which is due to the lack of an exocyclic double bond. It 
could also be the type and substitution pattern of the functional groups.        
Structural comparison of compound 2 and compound 3, specifically looking at the 3-
benzylidene-4-chromanone isomer 3a, we see that compound 3 is bulkier than compound 2 
because of the extra functional group at C-3‟ “R6” which could present issues with regard to 
binding of this compound in the active site. Additionally, because compound 3 was isolated 
as two isomers, it is possible that these two compounds could have an antagonistic effect on 
each other and, hence, we could not observe any biological activity. This, in relation to 
pharmacological activity, could be the reasons why 3a was inactive while 2 was active. 
In summary, compound 2 could be active because it has a molecular weight less than 500 
g/mol. Therefore, Clog P would be less than 5 (Lipinski et al., 1997) and it also appears to be 
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less bulky, reduced steric hindrance which will allow for easier access to the active site of 
RT. Compound 1 is not active probably because it lacks a double bond between C-3 and C-9 
which would make this compound flexible and prevent it from forming stable bond 
interactions in the active site. Furthermore, it has 2 methoxy functional groups and a hydroxyl 
group which could be attached at either C-5, C-7 or C-8 of the chromane moiety and C-4' 
which results hampering the bioactivity as seen from the studies of Desideri et al., (2011); 
Roy et at., (2013) and Tait et at., (2006).  
We, therefore, further assume that the reasons why compounds 1 and 3 were inactive while 2 
was active is because of their backbone structures and more so, the type of functional groups 
attached and their spatial positioning on the backbone structure of these compounds. 
However, these assumptions can only be verified by X-ray crystallography and computational 
studies utilizing fully elucidated chemical structures.                                  
To further discuss and account for the lack of direct anti-HIV-1 activity by compounds 1 and 
3, we propose that these could have anti-inflammatory and antioxidant activities which have 
been implicated in accelerating the progress of HIV infection. As stated above, studies have 
shown that homoisoflavones possess inhibitory activity against the enzymes Cox-1 and Cox-
2 which are crucial in initiating the inflammatory action. (Du Toit et al., 2010). The authors 
found that the 3-benzyl-4-chromanone types have potent activity against prostaglandin 
synthesis and Cox 1 & 2 enzyme activity when compared to the 3-benzylidene-4-chromanone 
type such as compound 2.  
The chomanone “3-benzyl-chrom-2-en-4-one” compounds have also been shown to possess 
antioxidant properties. They were more potent when compared to 3-benzyl-4-chromanone 
types. Furthermore, the type of functional group also played a role in enhancing their 
antioxidant activity i.e. a hydroxyl group favored potent activity while a methoxy group 
favored moderate activity (Rao et al., 2008).  
Overall, our data suggest that the ethanol- and dereplicated ethanol- herbal extract has direct 
and indirect anti-HIV 1 activity. These extracts possess a cocktail of phytochemicals that can 
inhibit HIV-1 RT and HIV-1 entry while, on the other hand, ensuring that the inflammatory 
responses activated during the infection are reduced thus reducing the number new cells 
infected during the course of the HIV 1 infection. Moreover, it possesses phytochemicals that 
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have antioxidant activity which, in relation to HIV infection, results in a boosted immune 
system to ward off the virus. This, then, translates to a decelerated progression of the AIDS 
state of patients who are HIV positive. 
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FUTURE WORK 
The main objective will be to elucidate the chemical structures of these compounds and to 
compute their molecular masses utilizing the capabilities of both 1D & 2D-NMR 
spectroscopy and HR-Q-TOF-MS. These techniques will provide data pertaining to the type 
and/or class of compound, chemical substituents and spatial location of the substituents 
within the molecules. This will, therefore, enable the construction of 2D chemical structures 
of these molecules to be used to obtain the accurate molecular mass and molecular 
fragmentation patterns.  
Furthermore, the compounds whose chemical structures and molecular masses have been 
solved could be used in the molecular modeling and molecular dynamic simulation studies. 
These studies are done in order to understand how these molecules interact chemically with 
their protein targets at the molecular level. These techniques afford us the ability to evaluate 
and predict the stable chemical configurations and chemical bonding interactions of these 
compounds.  
The findings of these studies may have important implications/applications in the fields of 
chemistry which include extensive knowledge application of analytical techniques in the 
industry. Also, the knowledge and understanding gained from these studies could lead to the 
discovery of new molecules which possess special characteristics important in 
pharmaceutical industries and may also have broader applications in the field of science and 
engineering.  
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